AU2017246664B2 - Fungal species, compositions derived therefrom, and uses thereof - Google Patents
Fungal species, compositions derived therefrom, and uses thereof Download PDFInfo
- Publication number
- AU2017246664B2 AU2017246664B2 AU2017246664A AU2017246664A AU2017246664B2 AU 2017246664 B2 AU2017246664 B2 AU 2017246664B2 AU 2017246664 A AU2017246664 A AU 2017246664A AU 2017246664 A AU2017246664 A AU 2017246664A AU 2017246664 B2 AU2017246664 B2 AU 2017246664B2
- Authority
- AU
- Australia
- Prior art keywords
- enzymes
- activity
- microorganisms
- extremophilic
- fungal species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 107
- 230000002538 fungal effect Effects 0.000 title claims abstract description 68
- 102000004190 Enzymes Human genes 0.000 claims abstract description 77
- 108090000790 Enzymes Proteins 0.000 claims abstract description 77
- 241000894007 species Species 0.000 claims abstract description 66
- 238000004519 manufacturing process Methods 0.000 claims abstract description 32
- 239000002351 wastewater Substances 0.000 claims abstract description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 10
- 229910021529 ammonia Inorganic materials 0.000 claims abstract description 8
- 239000003337 fertilizer Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 98
- 229940088598 enzyme Drugs 0.000 claims description 77
- 230000000694 effects Effects 0.000 claims description 52
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 42
- 244000005700 microbiome Species 0.000 claims description 41
- 235000010335 lysozyme Nutrition 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 108010014251 Muramidase Proteins 0.000 claims description 37
- 102000016943 Muramidase Human genes 0.000 claims description 37
- 239000004325 lysozyme Substances 0.000 claims description 37
- 229960000274 lysozyme Drugs 0.000 claims description 37
- 241000193738 Bacillus anthracis Species 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 24
- 108091005804 Peptidases Proteins 0.000 claims description 22
- 238000012545 processing Methods 0.000 claims description 22
- 102000035195 Peptidases Human genes 0.000 claims description 21
- 239000000758 substrate Substances 0.000 claims description 20
- 101150035093 AMPD gene Proteins 0.000 claims description 19
- 239000004365 Protease Substances 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 17
- 102000004316 Oxidoreductases Human genes 0.000 claims description 16
- 108090000854 Oxidoreductases Proteins 0.000 claims description 16
- 241000233866 Fungi Species 0.000 claims description 14
- 230000007613 environmental effect Effects 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 claims description 12
- 239000011521 glass Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 10
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 10
- 108010084185 Cellulases Proteins 0.000 claims description 9
- 102000005575 Cellulases Human genes 0.000 claims description 9
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 8
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 8
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 8
- 239000004382 Amylase Substances 0.000 claims description 8
- 108010065511 Amylases Proteins 0.000 claims description 8
- 102000013142 Amylases Human genes 0.000 claims description 8
- 102000004157 Hydrolases Human genes 0.000 claims description 8
- 108090000604 Hydrolases Proteins 0.000 claims description 8
- 102000015439 Phospholipases Human genes 0.000 claims description 8
- 108010064785 Phospholipases Proteins 0.000 claims description 8
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 8
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 8
- 102000006382 Ribonucleases Human genes 0.000 claims description 8
- 108010083644 Ribonucleases Proteins 0.000 claims description 8
- 108010049351 adenosine nucleosidase Proteins 0.000 claims description 8
- 235000019418 amylase Nutrition 0.000 claims description 8
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 8
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 8
- 108010089807 chitosanase Proteins 0.000 claims description 8
- 235000019419 proteases Nutrition 0.000 claims description 8
- 108700023418 Amidases Proteins 0.000 claims description 7
- 108090001060 Lipase Proteins 0.000 claims description 7
- 102000004882 Lipase Human genes 0.000 claims description 7
- 239000004367 Lipase Substances 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 102000005922 amidase Human genes 0.000 claims description 7
- 229940065181 bacillus anthracis Drugs 0.000 claims description 7
- 235000019421 lipase Nutrition 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 7
- 239000010802 sludge Substances 0.000 claims description 7
- 108010046334 Urease Proteins 0.000 claims description 6
- 108010036467 butanediol dehydrogenase Proteins 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- WHOOUMGHGSPMGR-UHFFFAOYSA-N indol-3-ylacetaldehyde Chemical compound C1=CC=C2C(CC=O)=CNC2=C1 WHOOUMGHGSPMGR-UHFFFAOYSA-N 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 238000001223 reverse osmosis Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 claims description 6
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 claims description 6
- 229940023877 zeatin Drugs 0.000 claims description 6
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 claims description 5
- 108010022172 Chitinases Proteins 0.000 claims description 5
- 102000012286 Chitinases Human genes 0.000 claims description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 5
- 102000000340 Glucosyltransferases Human genes 0.000 claims description 5
- 108010055629 Glucosyltransferases Proteins 0.000 claims description 5
- 239000000498 cooling water Substances 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000002101 lytic effect Effects 0.000 claims description 5
- 238000005555 metalworking Methods 0.000 claims description 5
- 108010069819 peptidoglycan endopeptidase Proteins 0.000 claims description 5
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims description 4
- 102000004008 5'-Nucleotidase Human genes 0.000 claims description 4
- 108700004024 5'-Nucleotidase Proteins 0.000 claims description 4
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical compound Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 claims description 4
- 108010092060 Acetate kinase Proteins 0.000 claims description 4
- 108010002945 Acetoin dehydrogenase Proteins 0.000 claims description 4
- 108010000700 Acetolactate synthase Proteins 0.000 claims description 4
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 claims description 4
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 claims description 4
- 102100032534 Adenosine kinase Human genes 0.000 claims description 4
- 108010076278 Adenosine kinase Proteins 0.000 claims description 4
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 claims description 4
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 claims description 4
- 108090000489 Carboxy-Lyases Proteins 0.000 claims description 4
- 102000004031 Carboxy-Lyases Human genes 0.000 claims description 4
- 102000003813 Cis-trans-isomerases Human genes 0.000 claims description 4
- 108090000175 Cis-trans-isomerases Proteins 0.000 claims description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 4
- 108010028143 Dioxygenases Proteins 0.000 claims description 4
- 102000016680 Dioxygenases Human genes 0.000 claims description 4
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims description 4
- 102000004533 Endonucleases Human genes 0.000 claims description 4
- 108010042407 Endonucleases Proteins 0.000 claims description 4
- 108060002716 Exonuclease Proteins 0.000 claims description 4
- 108050004645 Indole-3-pyruvate decarboxylases Proteins 0.000 claims description 4
- 108010018080 L-arabinose isomerase Proteins 0.000 claims description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 4
- 108090000913 Nitrate Reductases Proteins 0.000 claims description 4
- 108010025915 Nitrite Reductases Proteins 0.000 claims description 4
- 108010020943 Nitrogenase Proteins 0.000 claims description 4
- 101710163270 Nuclease Proteins 0.000 claims description 4
- 108700023175 Phosphate acetyltransferases Proteins 0.000 claims description 4
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 4
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 4
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 claims description 4
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims description 4
- 102000005262 Sulfatase Human genes 0.000 claims description 4
- 102000003929 Transaminases Human genes 0.000 claims description 4
- 108090000340 Transaminases Proteins 0.000 claims description 4
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 claims description 4
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 claims description 4
- 108700040099 Xylose isomerases Proteins 0.000 claims description 4
- 102100029089 Xylulose kinase Human genes 0.000 claims description 4
- 108030000293 Zeatin reductases Proteins 0.000 claims description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 4
- 229950006790 adenosine phosphate Drugs 0.000 claims description 4
- 229960003767 alanine Drugs 0.000 claims description 4
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 claims description 4
- 102000013165 exonuclease Human genes 0.000 claims description 4
- 108010056100 indole-3-acetamide hydrolase Proteins 0.000 claims description 4
- 108010079535 indoleacetamide hydrolase Proteins 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 235000019833 protease Nutrition 0.000 claims description 4
- 239000002336 ribonucleotide Substances 0.000 claims description 4
- 108060007951 sulfatase Proteins 0.000 claims description 4
- 108091022915 xylulokinase Proteins 0.000 claims description 4
- 108010011619 6-Phytase Proteins 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 102000004366 Glucosidases Human genes 0.000 claims description 3
- 108010056771 Glucosidases Proteins 0.000 claims description 3
- 108090000416 L-ribulose-5-phosphate 4-epimerases Proteins 0.000 claims description 3
- 108010033272 Nitrilase Proteins 0.000 claims description 3
- 101710202263 Nitrite reductase Proteins 0.000 claims description 3
- 108010050516 adenylate isopentenyltransferase Proteins 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 108010017919 indolyl-3-alkane-alpha-hydroxylase Proteins 0.000 claims description 3
- 229920005610 lignin Polymers 0.000 claims description 3
- 230000007918 pathogenicity Effects 0.000 claims description 3
- 229940085127 phytase Drugs 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- 101001066230 Gibberella fujikuroi (strain CBS 195.34 / IMI 58289 / NRRL A-6831) Cytochrome P450 monooygenase 2 Proteins 0.000 claims description 2
- 101000763602 Manilkara zapota Thaumatin-like protein 1 Proteins 0.000 claims description 2
- 101000763586 Manilkara zapota Thaumatin-like protein 1a Proteins 0.000 claims description 2
- 101000966653 Musa acuminata Glucan endo-1,3-beta-glucosidase Proteins 0.000 claims description 2
- 108010059820 Polygalacturonase Proteins 0.000 claims description 2
- 229910000831 Steel Inorganic materials 0.000 claims description 2
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 2
- 108010062085 ligninase Proteins 0.000 claims description 2
- 239000010959 steel Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 abstract description 57
- 238000011282 treatment Methods 0.000 abstract description 31
- 108090000623 proteins and genes Proteins 0.000 abstract description 21
- 238000011109 contamination Methods 0.000 abstract description 19
- 230000001580 bacterial effect Effects 0.000 abstract description 13
- 238000004140 cleaning Methods 0.000 abstract description 13
- 239000002551 biofuel Substances 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract description 8
- 206010052428 Wound Diseases 0.000 abstract description 8
- 230000003612 virological effect Effects 0.000 abstract description 8
- 208000027418 Wounds and injury Diseases 0.000 abstract description 6
- 239000004202 carbamide Substances 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 208000026721 nail disease Diseases 0.000 abstract description 6
- 208000017520 skin disease Diseases 0.000 abstract description 6
- 229920002472 Starch Polymers 0.000 abstract description 5
- 235000019698 starch Nutrition 0.000 abstract description 5
- 239000008107 starch Substances 0.000 abstract description 5
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 4
- 210000002700 urine Anatomy 0.000 abstract description 4
- 239000001569 carbon dioxide Substances 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 239000000054 fungal extract Substances 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 33
- 239000010902 straw Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- 230000000845 anti-microbial effect Effects 0.000 description 24
- 241000034280 Bacillus anthracis str. Sterne Species 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 230000012010 growth Effects 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 108010067770 Endopeptidase K Proteins 0.000 description 12
- 239000010907 stover Substances 0.000 description 12
- 229920001817 Agar Polymers 0.000 description 11
- 239000002028 Biomass Substances 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000000835 fiber Substances 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 240000008042 Zea mays Species 0.000 description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 8
- 235000005822 corn Nutrition 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 229910001220 stainless steel Inorganic materials 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 150000007523 nucleic acids Chemical group 0.000 description 7
- -1 sawdust Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000193403 Clostridium Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 240000000111 Saccharum officinarum Species 0.000 description 6
- 235000007201 Saccharum officinarum Nutrition 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 5
- 235000006008 Brassica napus var napus Nutrition 0.000 description 5
- 240000000385 Brassica napus var. napus Species 0.000 description 5
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 5
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 5
- 240000005979 Hordeum vulgare Species 0.000 description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 description 5
- 241000187654 Nocardia Species 0.000 description 5
- 241000192608 Phormidium Species 0.000 description 5
- 229920001131 Pulp (paper) Polymers 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000011121 hardwood Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000033458 reproduction Effects 0.000 description 5
- 239000011122 softwood Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000359166 Byssochlamys verrucosa Species 0.000 description 4
- 241000135254 Cephalosporium sp. Species 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 241000933069 Lachnoclostridium phytofermentans Species 0.000 description 4
- 240000003433 Miscanthus floridulus Species 0.000 description 4
- 241001263478 Norovirus Species 0.000 description 4
- 241000684698 Paecilomyces sp. (in: Hypocreales) Species 0.000 description 4
- 241001520808 Panicum virgatum Species 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 244000081757 Phalaris arundinacea Species 0.000 description 4
- 241000030452 Rasamsonia byssochlamydoides Species 0.000 description 4
- 241000746413 Spartina Species 0.000 description 4
- 241001561391 Sphaerospora Species 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 241000228341 Talaromyces Species 0.000 description 4
- 241000186339 Thermoanaerobacter Species 0.000 description 4
- 241001147775 Thermoanaerobacter brockii Species 0.000 description 4
- 241001137870 Thermoanaerobacterium Species 0.000 description 4
- 241000193446 Thermoanaerobacterium thermosaccharolyticum Species 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 241000193453 [Clostridium] cellulolyticum Species 0.000 description 4
- 239000002154 agricultural waste Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 238000004362 fungal culture Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000609240 Ambelania acida Species 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000221955 Chaetomium Species 0.000 description 3
- 241000209082 Lolium Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000712655 Papulaspora Species 0.000 description 3
- 241000139995 Paratritirachium cylindroconium Species 0.000 description 3
- 241000228143 Penicillium Species 0.000 description 3
- 241000193448 Ruminiclostridium thermocellum Species 0.000 description 3
- 241001137871 Thermoanaerobacterium saccharolyticum Species 0.000 description 3
- 241001494489 Thielavia Species 0.000 description 3
- 241000182985 Thielavia australiensis Species 0.000 description 3
- 241001337590 Tritirachium sp. (in: Ascomycota) Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000010905 bagasse Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- 241000208140 Acer Species 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000838140 Acrophialophora fusispora Species 0.000 description 2
- 208000003120 Angiofibroma Diseases 0.000 description 2
- 241001520170 Anoxybacillus gonensis Species 0.000 description 2
- 241001487119 Anoxybacillus kamchatkensis Species 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 241000235349 Ascomycota Species 0.000 description 2
- 241000131314 Aspergillus candidus Species 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- 241000740945 Botrytis sp. Species 0.000 description 2
- 241000079253 Byssochlamys spectabilis Species 0.000 description 2
- 241001626339 Calcarisporium Species 0.000 description 2
- 241000178957 Caldanaerobius polysaccharolyticus Species 0.000 description 2
- 241000321602 Caldanaerobius zeae Species 0.000 description 2
- 241000887245 Caldicellulosiruptor acetigenus Species 0.000 description 2
- 241000511681 Caldicellulosiruptor kristjanssonii Species 0.000 description 2
- 241000511679 Caldicellulosiruptor lactoaceticus Species 0.000 description 2
- 241000556413 Caldicellulosiruptor owensensis Species 0.000 description 2
- 241000178335 Caldicellulosiruptor saccharolyticus Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 241000088530 Chaetomium sp. Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000603729 Geotrichum sp. Species 0.000 description 2
- 241000223200 Humicola grisea var. thermoidea Species 0.000 description 2
- 241001480714 Humicola insolens Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010066295 Keratosis pilaris Diseases 0.000 description 2
- 241000862991 Leptothrix <Bacteria> Species 0.000 description 2
- 241000144128 Lichtheimia corymbifera Species 0.000 description 2
- 241001184659 Melanocarpus albomyces Species 0.000 description 2
- 241001331072 Microbispora rosea subsp. aerata Species 0.000 description 2
- 241000235575 Mortierella Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 241000192497 Oscillatoria Species 0.000 description 2
- 241000933952 Paenibacillus campinasensis Species 0.000 description 2
- 241000193390 Parageobacillus thermoglucosidasius Species 0.000 description 2
- 208000009675 Perioral Dermatitis Diseases 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 241000219000 Populus Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000219492 Quercus Species 0.000 description 2
- 241000985315 Rasamsonia argillacea Species 0.000 description 2
- 241000959173 Rasamsonia emersonii Species 0.000 description 2
- 241000235403 Rhizomucor miehei Species 0.000 description 2
- 241000135252 Rhizomucor sp. Species 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 241001147742 Saccharococcus Species 0.000 description 2
- 241000124033 Salix Species 0.000 description 2
- 241001524053 Scolecobasidium sp. Species 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 241001279813 Sepedonium Species 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 244000138286 Sorghum saccharatum Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 241001085826 Sporotrichum Species 0.000 description 2
- 241001626291 Stilbella Species 0.000 description 2
- 241000187177 Streptomyces thermovulgaris Species 0.000 description 2
- 241001464792 Synechococcus lividus Species 0.000 description 2
- 241001659671 Talaromyces piceae Species 0.000 description 2
- 241000186337 Thermoanaerobacter ethanolicus Species 0.000 description 2
- 241000216452 Thermoanaerobacterium aotearoense Species 0.000 description 2
- 241001468159 Thermoanaerobacterium thermosulfurigenes Species 0.000 description 2
- 241001147773 Thermoanaerobacterium xylanolyticum Species 0.000 description 2
- 241000228178 Thermoascus Species 0.000 description 2
- 241000228182 Thermoascus aurantiacus Species 0.000 description 2
- 241000228184 Thermoascus crustaceus Species 0.000 description 2
- 241000202344 Thermoflavimicrobium dichotomicum Species 0.000 description 2
- 241000223257 Thermomyces Species 0.000 description 2
- 241001136490 Thermomyces dupontii Species 0.000 description 2
- 241000205204 Thermoproteus Species 0.000 description 2
- 241001313536 Thermothelomyces thermophila Species 0.000 description 2
- 241000204652 Thermotoga Species 0.000 description 2
- 241000605118 Thiobacillus Species 0.000 description 2
- 241000006364 Torula Species 0.000 description 2
- 101710115637 Zeatin O-glucosyltransferase Proteins 0.000 description 2
- 241000193445 [Clostridium] stercorarium Species 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 208000009621 actinic keratosis Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000004378 air conditioning Methods 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000003225 biodiesel Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000004567 concrete Substances 0.000 description 2
- 238000005202 decontamination Methods 0.000 description 2
- 230000003588 decontaminative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012978 lignocellulosic material Substances 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 239000004579 marble Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052573 porcelain Inorganic materials 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241001495177 Acetivibrio cellulolyticus Species 0.000 description 1
- 241001109646 Acetivibrio ethanolgignens Species 0.000 description 1
- 241000605272 Acidithiobacillus thiooxidans Species 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000447456 Alkalibacter Species 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 241001455623 Anaerocellum Species 0.000 description 1
- 241001485848 Anagnostidinema amphibium Species 0.000 description 1
- 241001626813 Anoxybacillus Species 0.000 description 1
- 241001468259 Anoxybacillus flavithermus Species 0.000 description 1
- 241000192698 Aphanocapsa Species 0.000 description 1
- 241000205046 Archaeoglobus Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000853001 Bacillus cereus E33L Species 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 241000193417 Brevibacillus laterosporus Species 0.000 description 1
- 240000005430 Bromus catharticus Species 0.000 description 1
- 241001429558 Caldicellulosiruptor bescii Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001619326 Cephalosporium Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000192731 Chloroflexus aurantiacus Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000002309 Collariella virescens Species 0.000 description 1
- 241000222511 Coprinus Species 0.000 description 1
- 241000206584 Cyanidium caldarium Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 241001490735 Cyclidium Species 0.000 description 1
- 241000186541 Desulfotomaculum Species 0.000 description 1
- 241000205236 Desulfurococcus Species 0.000 description 1
- 101100256910 Drosophila melanogaster sick gene Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000775913 Escallonia pulverulenta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000605896 Fibrobacter succinogenes Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000605108 Flavobacterium johnsoniae Species 0.000 description 1
- 108700005088 Fungal Genes Proteins 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 241000896533 Gliocladium Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000223198 Humicola Species 0.000 description 1
- 241000271815 Hydrogenimonas Species 0.000 description 1
- 241000222342 Irpex Species 0.000 description 1
- 241000580733 Kamptonema okenii Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241001503905 Laceyella sacchari Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186866 Lactobacillus thermophilus Species 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 241000193386 Lysinibacillus sphaericus Species 0.000 description 1
- 241000228423 Malbranchea Species 0.000 description 1
- 241001154030 Malbranchea pulchella Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001647400 Mastigocladus laminosus Species 0.000 description 1
- 241000202974 Methanobacterium Species 0.000 description 1
- 241001302042 Methanothermobacter thermautotrophicus Species 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 241000193459 Moorella thermoacetica Species 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- 241000625698 Mycogone Species 0.000 description 1
- 241000223251 Myrothecium Species 0.000 description 1
- 101710126437 N-acetylmuramyl-L-alanine amidase Proteins 0.000 description 1
- 241000382366 Nodulisporium Species 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241000058854 Oscillatoria terebriformis Species 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 241000178960 Paenibacillus macerans Species 0.000 description 1
- 241001621940 Parageobacillus caldoxylosilyticus Species 0.000 description 1
- 241000250930 Penicillata Species 0.000 description 1
- 241001453201 Phormidium laminosum Species 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241001495182 Pseudobacteroides cellulosolvens Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000187602 Pseudonocardia thermophila Species 0.000 description 1
- 241000205226 Pyrobaculum Species 0.000 description 1
- 241000205160 Pyrococcus Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 241000204671 Pyrodictium Species 0.000 description 1
- 241000531165 Pyrodictium abyssi Species 0.000 description 1
- 241001494984 Pyrodictium brockii Species 0.000 description 1
- 241000204670 Pyrodictium occultum Species 0.000 description 1
- 241000125139 Saccharomonospora azurea Species 0.000 description 1
- 241001670248 Saccharophagus degradans Species 0.000 description 1
- 241000122799 Scopulariopsis Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 235000016536 Sporobolus cryptandrus Nutrition 0.000 description 1
- 241001279361 Stachybotrys Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000205219 Staphylothermus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000205101 Sulfolobus Species 0.000 description 1
- 241000205098 Sulfolobus acidocaldarius Species 0.000 description 1
- 241001512067 Symploca Species 0.000 description 1
- 241000192707 Synechococcus Species 0.000 description 1
- 241001453296 Synechococcus elongatus Species 0.000 description 1
- 241000192584 Synechocystis Species 0.000 description 1
- 241000203770 Thermoactinomyces vulgaris Species 0.000 description 1
- 241000207200 Thermoanaerobacter acetoethylicus Species 0.000 description 1
- 241000193447 Thermoanaerobacter thermohydrosulfuricus Species 0.000 description 1
- 241000203600 Thermobispora bispora Species 0.000 description 1
- 241000205188 Thermococcus Species 0.000 description 1
- 241000205180 Thermococcus litoralis Species 0.000 description 1
- 241000605782 Thermodesulfobacterium thermophilum Species 0.000 description 1
- 241000531244 Thermodiscus Species 0.000 description 1
- 241000589017 Thermomicrobium roseum Species 0.000 description 1
- 241000203640 Thermomonospora Species 0.000 description 1
- 241000203783 Thermomonospora curvata Species 0.000 description 1
- 241000204667 Thermoplasma Species 0.000 description 1
- 241000204673 Thermoplasma acidophilum Species 0.000 description 1
- 241000204315 Thermosipho <sea snail> Species 0.000 description 1
- 241001495113 Thermostaphylospora chromogena Species 0.000 description 1
- 241000229716 Thermothrix thiopara Species 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- 241000190807 Thiothrix Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000224494 Vahlkampfia Species 0.000 description 1
- 241001362380 Verruconis gallopava Species 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 241000317522 Youngiibacter multivorans Species 0.000 description 1
- 241001147803 [Clostridium] aldrichii Species 0.000 description 1
- 241000229117 [Clostridium] hungatei Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012225 czapek media Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 108091007735 digestive proteases Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000972 organotrophic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
- C09D7/40—Additives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Mycology (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Provided herein are secretory compositions/cocktails derived from a novel, extremophilic fungal species cultured, isolated, and characterized herein. Said novel, extremophilic fungal species may be exploited to produce secretory compositions/cocktails which comprise a unique mixture of thermo-tolerant, stable enzymes capable of digesting cellular and genetic material in its surroundings under extreme temperatures. Such secretory compositions/cocktails may be useful as cleaning and sterilization solutions against biofilm, urine, yeast, bacterial, or viral contamination. Other uses include, but are not limited to, urea removal, fertilizer wastewaters, wastewater reclamation for life support systems in space, pH control, source of ammonia and carbon dioxide, starch digestion, biofuel production, as pharmaceuticals, and medical treatments such as wounds, skin disorders, or nail disorders.
Description
APPLICATION FOR PATENT
CROSS-REFERENCE
This application claims the benefit of U.S. Provisional Application No.
62/318,597, filed April 5, 2016, the entirety of which is hereby incorporated by reference.
BACKGROUND
Thermophilic, psychrophilic, and mesophilic fungi may secrete a variety of enzymes useful for bioprocesses or other industrial applications. However, there has been very little effort to isolate, identify, and characterize new fungal species. Likewise, examination of extracellular production by thermophilic, psychrophilic, and mesophilic fungi has been sparse. While desirable characteristics of different fungal species could be exploited, the optimal conditions for culturing and enhancing potency of secretory enzymes vary greatly. Many variables influence the success of culturing, including but not limited to: temperature, pH, growth medium, lighting conditions, time periods, agitation, supplements and chemicals added. Identifying the small and unpredictable window of conditions suitable for isolating novel fungal species, while simultaneously generating compositions of enzymes having enhanced potency, high/low temperature optima, and stability, presents a significant challenge.
SUMMARY
Provided herein are secretory compositions derived from a novel, extremophilic fungal species cultured, isolated, characterized and sequenced herein. Said novel, extremophilic fungal species may be exploited to produce secretory compositions or "cocktail" of compositions (sometimes referred to herein as "compositions/cocktails") which comprise a unique mixture of thermo-tolerant, stable enzymes capable of digesting cellular and genetic material even under extreme temperatures. Such secretory compositions/cocktails may be useful as cleaning and sterilization solutions against biofilms, urine, yeast, metazoan, bacterial, or viral contamination. Other uses include, but are not limited to, urea removal, fertilizer wastewaters, wastewater reclamation for life support systems in space, pH control, source of ammonia and carbon dioxide, starch
digestion, chitin digestion, cell digestion, biofuel production, as pharmaceuticals, and medical treatments such as wounds, skin disorders, or nail disorders. Additional properties may be provided by adding other proteins, peptides, chemicals or small molecules (e.g. lysozyme, ampD from Bacillus (a, Bacillus anthracis killer) colloidal silver, other cell wall digestive enzymes, and proteases antimicrobial peptides) (See, for example, Bourguet et al. Applied Environmental Microbiology, 2012, and Vollmer et al, FEMS Microbial Rev 32 (2008) 259-286).
One aspect of the invention relates to a secretory composition derived from an extremophilic fungal species comprising one or more enzymes selected from the group consisting of urease, DNase, RNase, exonuclease, endonuclease, ribonuclease, amylase, acetoin reductase, an indole-3-acetamide hydrolase, a tryptophan monooxygenase, an acetolactate synthetase, an a-acetolactate decarboxylase, a pyruvate decarboxylase, a diacetyl reductase, a butanediol dehydrogenase, an aminotransferase, a tryptophan decarboxylase, an amine oxidase, an indole-3 -pyruvate decarboxylase, an indole-3- acetaldehyde dehydrogenase, a tryptophan side chain oxidase, a nitrile hydrolase, a nitrilase, a peptidase, a protease, an adenosine phosphate isopentenyltransferase, a phosphatase, an adenosine kinase, an adenine phosphoribosyl transferase, CYP735A, a 5'ribonucleotide phosphohydrolase, an adenosine nucleosidase, a zeatin cis-trans isomerase, a zeatin O-glucosyltransferase, a β-glucosidase, acis-hydroxylase, a CK cis- hydroxylase, a CK N-glucosyltransferase,a2,5-ribonucleotide phosphohydrolase, an adenosine nucleosidase, a purine nucleoside phosphorylase, a zeatin reductase, a hydroxylamine reductase, a 2-oxoglutarate dioxygenase, a gibberellic 2B/3B hydrolase, a gibberellin 3-oxidase, a gibberellin 20-oxidase, a chitosanase, a chitinase, a β-1,3- glucanase, a P-l,4-glucanase, a P-l,6-glucanase, an aminocyclopropane-l-carboxylic acid deaminase, chitosanase, acellulase, a lipase, alignin oxidase, a protease, a glycoside hydrolase, a phosphatase, a nitrogenase, a nuclease, an amidase, a nitrate reductase, a nitrite reductase, an amylase, an ammonia oxidase, aligninase, aglucosidase, a phospholipase, aphytase, apectinase, a glucanase, a sulfatase, a xylanase, an endocellulase, an exocellulase, a β-glucosidase, phospholipase, acetate kinase, phosphotransacetylase, lactate dehydrogenase, pyruvate decarboxylase (PDC), alcohol dehydrogenase (ADH), xylose isomerase, xylulokinase, L- arabinose isomerase, L-ribulose- 5-phosphate 4-epimerase, a glycan strand-cleaving enzyme/glycosidase, N-
acetylglucosaminidase, acetylmuramyl-L-alanine amidase, lysozyme, lytic transglycosylase and peptidoglycan endopeptidase.
In some embodiments, the composition comprises ampD.
In some embodiments, the composition comprises lysozyme.
In some embodiments, the composition comprises phi29 lysozyme.
In some embodiments, the composition comprises two, three, four, five, six, seven, eight, nine, or ten enzymes.
In some embodiments, the one or more enzymes have a 25-, 30-, 35-, 40-, 45-, 50-, 55-, 60-, 65-, 70-, 75-, 80-, 85-, 90-, 95-, 100-, 105-, 110-, 115-, 120-, 125-, 130-, 135-, 140-, 145-, 150-, 155-, 160-, 165-, 170-, 175-, 180-, 185-, 190-, 195-, or 200-fold increase in specific activity when purified using size exclusion chromatography in combination with an affinity based membrane purification system.
In some embodiments, the one or more enzymes is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% pure.
In some embodiments, the extremophilic fungal species is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% homologous to aknown thermophilic, psychrophilic, ormesophilic fungal species.
In some embodiments, the thermophilic fungal species is selected from the group consisting of TM-417, Zygomycetes, Absidia corymbifera, Mortierella turflcola, M wolfl, Mucor miehei, Mpusillus, Rhizomucor sp., Rhizopus arrhizus, Chaetomium sp., R cohnii, R. microspores, Ascomycetes, Allescheria terrestris, Byssochlamys verrucosa, Chaetomium britannicum, C. thermophile, C. thermophile var. coprophile, C.
thermophile var. dissitum, C. virginicum, Emericella nidulans, Hansertula polymorpha, Myriococcum albomyces, Sphaerospora saccata, Talaromyces byssochlamydoides, T emersonii, T leycettanus, T thermophiles, Thermoascus aurantiacus, Tcrustaceus, Thielavia auslraliensis, T sepedonium, T thermophile. Basidiomycetes, Coprirms delicatulus, Mycelia Sterila, Burgoa-Papulaspora, Papulaspora thermophile,
Deuteromycetes, Acremomum albamensis, Acrophialophorafusispora, Aspergillus candidus, A. fiimigatus, Botrytis sp.. Sphaerospora saccata, Calcarisporium
thermophile, Cephalosporium sp., Allescheria terrestris. Cephalosporium sp., Thielavia australiensis, Geotrichum sp. A, Humicola grisea var. thermoidea, H. insolens, H.
lamiginose, H. stellate, Malbranchea pulchella var. suljurea, Nodulisporium
cylindroconium, Tritirachiumsp.A, Paecilomyces crustaceus, Thermoascus, P. puntonii, P. variotii, Paecilomyces sp., Byssochlamys verrucosa, Paecilomyces sp., Talaromyces byssochlamydoides, Penicillium duponti Talaromyces thermophilus, P. emersonii Talaromyces, P. leycettanum Talaromyces. P. piceum, P. argillaceum, Ptychogaster sp., Sporotrichum pulverulentum, Scolecobasidium sp. A, Diplorhinotrichum galloparum, Sporotrichum thermophile, Thielavia, S. pulverulentum, Stilbella thermophile,
Thermomyces ibadanesis, Torula thermophile, Torulopsis Candida, Tritirachium sp. A, and Nodulisporium cylindroconium.
In some embodiments, the thermophilic fungal species is TM-417.
In some embodiments, any of the compositions of the present invention as a clean solution. In some embodiments, any of the compositions of the present invention as a titratable self-destruct composition - slow release - slowdestruct.
In some embodiments, any of the compositions of the present invention as a slow release solution comprising any of the compositions of the present invention.
Another aspect of the invention relates to a recombinant extremophilic fungal species comprising at least one heterologous gene, said gene enhances or increases the potency of any of the compositions of the present invention. In some embodiments, the recombinant extremophilic fungal species comprises a mutation, substitution, deletion, addition, insertion, or replacement.
In some embodiments, the recombinant comprises at least two, three, four, or five, heterologous genes.
Another aspect of the invention relates to a method for treating a contaminated surface, comprising the step of contacting the contaminated surface with an effective amount of any of the compositions ofthe present invention.
In some embodiments, the contaminated surface comprises a biofilm, bacterial, fungal, viral, or yeast growth.
In some embodiments, the contaminated surface comprises Bacillus anthracis.
Another aspect of the invention relates to a method for decontaminating or sterilizing a product or system comprising the step of contacting the product or system with the composition of claim 1, wherein the product or system is selected from the group consisting of medical device, clinical product, agricultural specimen,
environmental specimen, manufacturing sample, industrial system, transportation, marine system, and household system.
In some embodiments, the medical device is a catheter, stent, IV, or surgical tool. In some embodiments, the agricultural specimen is a food, farm product, water supply, waste water, fertilizer wastewater, orsludge.
In some embodiments, the environmental specimen is a lake, pond, fountain, or pool. In some embodiments, the clinical product is an artificial kidney dialysate.
In some embodiments, the manufacturing sample is a machine for processing samples.
In some embodiments, the industrial system is selected from the group consisting of a cooling water system, heat exchanger, pulp and paper manufacturing, food processing system, metalworking, photo processing, reverse osmosis membrane, water processing, flow channel, turbine, solar panel, pressurized water reactor, injection and spray nozzle, steam generator, process equipment, secondary oil recovery injection well, and piping.
In some embodiments, the marine system comprises offshore oil and gas pipeline, off-shore oil rig, environments within a cruise liner, boat or oil rig, or a boat hull.
In some embodiments, the household environment comprises cutting surface, sink, counter-top, shower, vase, pet food bowl, water bowl, decorative water landscaping, and bird baths.
Another aspect of the invention relates to a method for removing urea from a product or system comprising the step of contacting the product or system with the composition of claim 1, wherein the product or system is selected from the group consisting of medical device, clinical product, agricultural specimen, environmental specimen, manufacturing sample, industrial system, marine system, and household system.
Another aspect of the invention relates to a method for treating a wound comprising the step of contacting the surface of the injured area with a therapeutically effective amount of any of the compositions of the present invention.
In some embodiments, the wound is a cut, abrasion, open wound, sore, or abscess.
Another aspect of the invention relates to a method for treating a skin or nail disorder comprising the step of contacting the affected surface of the skin or nail with a therapeutically effective amount of any of the compositions of the present invention.
In some embodiments, the skin or nail disorder is selected from the group consisting of acne, actinic keratosis, alopecia areata, athlete's foot, onchomychosis, atopic dermatitis, osmidrosis, eczema, fungal infection of the nails, psoriasis, rosacea, slow wound healing, folliculitis, keratosis pilaris, perioral dermatitis, angiofibromas, cutaneous inflammation, aging damage, dyschromia, premature greying hair, and seborrhea.
Another aspect of the invention relates to a method of producing a biofuel comprising the step of contacting a biomass with an effective amount of the composition of any of the compositions of the present invention.
In some embodiments, the biofuel is selected from the group consisting of alcohol, ethanol, biodiesel, bioethanol, bioalcohol, green diesel, biofuel gasoline, vegetable oil, biogas, syngas, and solid biofuel.
In some embodiments, the biomass is selected from the group consisting of lignocellulosic material, woody biomass, recycled wood pulp fiber, sawdust, hardwood, softwood, algae, corn, sugarcane, sweet sorghum, trees, grass, switch grass, cord grass, rye grass, reed canary grass, miscanthus, sugar-processing residue, sugar cane bagasse; agricultural waste, rice straw, rice hulls, barley straw, com cobs, cereal straw, wheat straw, canola straw, oat straw, oat hulls, com fiber, stover, soybean stover, com stover, forestry waste, recycled wood pulp fiber, sawdust, hardwood, poplar, oak, maple, birch, willow, softwood, manure, wastewater, cereal straws, wheat straw, barley straw, canola straw, oat straw, and com fiber, or combinations thereof.
Another aspect of the invention relates to a method for reducing an amount or an activity of microorganisms, comprising: contacting a substrate comprising the
microorganisms with a composition comprising one or more enzymes derived from an extremophilic fungal species, thereby reducing the amount or the activity of the
microorganisms.
In some embodiments, the extremophilic fungal species is TM-417.
In some embodiments, the extremophilic fungal species is at least about 80% homologous to TM-417.
In some embodiments, the one or more enzymes comprise at least one enzyme selected from the group consisting of urease, DNase, RNase, exonuclease, endonuclease, ribonuclease, amylase, acetoin reductase, an indole-3 -acetamide hydrolase, a tryptophan monooxygenase, an acetolactate synthetase, an a-acetolactate decarboxylase, a pyruvate decarboxylase, a diacetyl reductase, abutanediol dehydrogenase, an aminotransferase, a tryptophan decarboxylase, an amine oxidase, an indole-3-pyruvate decarboxylase, an indoles' acetaldehyde dehydrogenase, a tryptophan side chain oxidase, a nitrile hydrolase, a nitrilase, a peptidase, a protease, an adenosine phosphate isopentenyltransferase, a phosphatase, an adenosine kinase, an adenine phosphoribosyltransferase, CYP735A, a 5'ribonucleotide phosphohydrolase, an adenosine nucleosidase, a zeatin cis-trans isomerase, a zeatin 0- glucosyltransferase, a β-glucosidase, a cis-hydroxylase, a CK cis-hydroxylase, a CKN- glucosyltransferase, a 2,5-ribonucleotide phosphohydrolase, an adenosine nucleosidase, a purine nucleoside phosphorylase, a zeatin reductase, a hydroxylamine reductase, a 2-oxoglutarate dioxygenase, agibberellic 2B/3B hydrolase, agibberellin 3- oxidase, agibberellin 20-oxidase, a chitosanase, a chitinase, a p-l,3-glucanase, a β-1,4- glucanase, a P-l,6-glucanase, an aminocyclopropane-l-carboxylic acid deaminase, chitosanase, a cellulase, a lipase, a lignin oxidase, a protease, a glycoside hydrolase, a phosphatase, a nitrogenase, a nuclease, an amidase, a nitrate reductase, a nitrite reductase, an amylase, an ammonia oxidase, a ligninase, a glucosidase, a phospholipase, a phytase, a pectinase, a glucanase, a sulfatase, a xylanase, an endocellulase, an exocellulase, a β- glucosidase, phospholipase, acetate kinase, phosphotransacetylase, lactate dehydrogenase, pyruvate decarboxylase (PDC), alcohol dehydrogenase (ADH), xylose isomerase, xylulokinase, L-arabinose isomerase, L-ribulose-5- phosphate 4-epimerase, a glycan strand- cleaving enzyme/glycosidase, N-acetylglucosaminidase, acetylmuramyl-L-alanine amidase, lysozyme, lytic transglycosylase and peptidoglycan endopeptidase.
In some embodiments, the one or more enzymes comprise two or more enzymes.
In some embodiments, the one or more enzymes comprise three or more enzymes.
In some embodiments, the one or more enzymes comprise four or more enzymes.
In some embodiments, the one or more enzymes have at least about a 25-fold increase in specific activity when purified using size exclusion chromatography in combination with an affinity based membrane purification system.
In some embodiments, the one or more enzymes have at least about a 100-fold
increase in specific activity when purified using size exclusion chromatography in combination with an affinity based membrane purification system.
In some embodiments, the one or more enzymes have at least about a 200-fold increase in specific activity when purified using size exclusion chromatography in combination with an affinity based membrane purification system.
In some embodiments, the one or more enzymes is at least about 50% pure.
In some embodiments, the one or more enzymes is at least about 75% pure.
In some embodiments, the one or more enzymes is at least about 95% pure.
In some embodiments, the composition comprises ampD.
In some embodiments, the composition comprises lysozyme.
In some embodiments, the composition comprises phi29 lysozyme.
In some embodiments, the microorganisms comprise bacteria, fungi, viruses, or yeast.
In some embodiments, the microorganisms comprise Bacillus anthracis.
In some embodiments, the activity of the microorganisms comprises pathogenicity. In some embodiments, the activity of the microorganisms comprises viability. In some embodiments, the activity of the microorganisms comprises reproduction. In some embodiments, the activity of the microorganisms comprises metabolism. In some embodiments, the activity of the microorganisms comprises toxin production.
In some embodiments, the amount or the activity of the microorganisms is reduced by at least about 10%.
In some embodiments, the amount or the activity of the microorganisms is reduced by at least about 50%.
In some embodiments, the amount or the activity of the microorganisms is reduced by at least about 70%.
In some embodiments, the amount or the activity' of the microorganisms is reduced by at least about 95%.
In some embodiments, the amount or the activity of the microorganisms is reduced by at least about 99%.
In some embodiments, the substrate comprises a liquid.
In some embodiments, the substrate comprises water.
In some embodiments, the substrate comprises a solid.
In some embodiments, the substrate comprises steel.
In some embodiments, the substrate comprises glass.
In some embodiments, the substrate is part of a product or system selected from the group consisting of medical device, clinical product, agricultural specimen, environmental specimen, manufacturing sample, industrial system, transportation, marine system, and household system.
In some embodiments, the medical device is a catheter, stent, IV, or surgical tool. In some embodiments, the agricultural specimen is a food, farm product, water supply, waste water, fertilizer wastewater, or sludge.
In some embodiments, the environmental specimen is a lake, pond, fountain, or pool.
In some embodiments, the clinical product is an artificial kidney dialysate.
In some embodiments, the manufacturing sample is a machine for processing samples.
In some embodiments, the industrial system is a cooling water system, a heat exchanger, a pulp and paper manufacturing system, food processing system, a metalworking system, a photo processing system, a reverse osmosis membrane, a water processing system, a flow channel, a turbine, a solar panel, a pressurized water reactor, an injection and spray nozzle, a steam generator, process equipment, a secondary oil recovery injection well, or piping.
In some embodiments, the marine system comprises an offshore oil and gas pipeline, off-shore oil rig, environments within a boat or oil rig, or a boat hull.
In some embodiments, the household environment comprises a cutting surface, a sink, a counter-top, a shower, a vase, a pet food bowl, a water bowl, decorative water landscaping, or a bird bath.
Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred
embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts the novel, extremophilic fungal cultures prior to extraction and stabilization of the enzyme cocktail. FIG. 1A shows balls of fungal hyphae produced in a rotating culture. FIG. IB shows mats of hyphae in a stationary culture.
FIG. 2 depicts an image of the novel, extremophilic fungal species.
FIG.3 shows an image of the bactericidal properties of the novel, extremophilic fungal species. The image shows a petri dish covered in bacteria and spotted with an enzyme composition isolated from the novel, extremophilic fungal species, and then grown for IS hours. The treated dish (right panel) showed dramatic bactericidal properties when compared to the untreated dish (left panel).
FIG.4 shows antimicrobial activity of fungal extract against B. anthracis Sterne in saline.
FIG.5 shows the effect of boiling and room temperature storage on the efficacy of fungal extract against B. anthracis.
FIG.6 shows the influence of water type on the efficacy of fungal extract against B. anthracis.
FIG. 7 shows the antimicrobial activity of fungal extract with supplemental compounds. FIG. 7A shows the antimicrobial activity of fungal extract against B. anthracis Sterne. FIG. 7B shows the antimicrobial activity of fungal extract with 10 units/mL of proteinase K and lysozyme. FIG. 7C shows the antimicrobial activity of fungal extract with 100 units/mL of proteinase K and lysozyme.
FIG.8 shows antimicrobial activity of fungal extract supplemented with ampD and phi29 lysozyme against B. anthracis Sterne.
FIG.9 shows the efficacy of fungal extract supplemented with ampD and phi29 lysozyme against Bacillus anthracis on stainless steel.
FIG. 10 shows the efficacy of fungal extract supplemented with ampD and phi29 lysozyme against Bacillus anthracis on glass.
DETAILED DESCRIPTION
I. Definitions
By "thermophilic" is meant an organism that is capable of growth and reproduction in higher temperatures, ranging from about 45 °C or higher.
By "mesophilic" is meant an organism mat thrives and is capable of growth and
reproduction in mild temperatures, ranging from about 20 °C to 45 °C.
By "psychrophilic" or cryophiles are organisms mat thrive and are capable of growth and reproduction in cold temperatures, ranging from about -20 °C to +20 °C.
The term "homologous" refers to the "% homology" and is used interchangeably herein with the term "% identity" herein, and relates to the level of nucleic acid sequence identity between novel, extremophilic fungal species when compared to known thermophilic or mesophilic fungal species, when aligned using a sequence alignment program.
For example, as used herein, 80% homology means the same thing as 80% sequence identity determined by a defined algorithm, and accordingly a homologue of a given sequence has greater than 80% sequence identity over a length of the given sequence. Exemplary levels of sequence identity include, but are not limited to about, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or more sequence identity of a novel, extremophilic fungal species when compared to known thermophilic or mesophilic fungal species.
Exemplary computer programs which can be used to determine identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, and TBLASTX, BLASTP and TBLASTN, publicly accessible at www.ncbi.nlm.nih.gov/BLAST.
Sequence searches are typically carried out using the BLASTN program when evaluating a given nucleic acid sequence relative to nucleic acid sequences in the GenBank DNA Sequences and other public databases. The BLASTX program can be used for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases.
The term "therapeutic effect" refers to a local or systemic effect in animals, particularly mammals, and more particularly humans, caused by a pharmacologically active substance.
The terms "therapeutically-effective amount" and "effective amount" as used herein means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired
therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
The term "treating" a disease in a subject or "treating" a subject having a disease refers to subjecting the subject to a pharmaceutical treatment, e.g., the administration of a secretory compositions/cocktails of the present invention, such that at least one symptom of the disease is decreased, prevented from worsening, or delayed from worsening. An "effective amount" or "a therapeutically effective amount," of a therapeutic agent refers to the amount of the agent necessary to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of an agent may vary depending on such factors as the desired biological endpoint, the agent to be delivered, the composition of the pharmaceutical composition, the target tissue or cell, and the like. More particularly, the term "effective amount" refers to an amount sufficient to produce the desired effect, e.g., to reduce or ameliorate the severity, duration, progression, or onset of a disease, disorder, or condition, or one or more symptoms thereof; prevent the advancement of a disease, disorder, or condition, cause the regression of a disease, disorder, or condition; prevent the recurrence, development, onset or progression of a symptom associated with a disease, disorder, or condition, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
II. Methods for Identifying Novel Fungal Species
Aspects of the present invention relate to methods for isolating and identifying novel, extremophilic fungal species. Such methods may comprise the placement of natural or unnatural nutrient sources within the environment to allow for concentration of the species at a site for collection, then within laboratory conditions, varying culture, plate, media, temperature, time periods, pH, or lighting conditions, or combinations thereof. Such methods may also comprise varying oxygen, carbon dioxide, carbon source, nitrogen source, fatty acid, nucleic acid, nutrient, vitamin, trace mineral, salt, ion, or amino acid levels, or combinations thereof.
In some embodiments, the temperature for incubating, culturing, or assaying components of the secretory compositions/cocktails may be -45 °C, -40 °C, -35 °C, -30 °C, -25 °C, -20 °C, - 15 °C, -10 °C, -5 °C, 0 °C, 5 °C, 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, 35 °C, 40 °C, 45 °C, 50 °C, 55 °C, 60 °C, 65 °C, 70 °C, 75 °C, 80 °C, 85 °C, 90 °C, 95
°C, or 100 °C. In certain embodiments, the invention relates to any one of the above- mentioned methods, wherein the temperature is from about 30 °C to about 75 °C. In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the temperature is from about 45 °C to about 75 °C. In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the temperature is from about 55 °C to about 65 °C. In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the temperature is about 45 °C. In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the temperature is about 55 °C. In certain embodiments, the invention relates to any one of the above- mentioned methods, wherein the temperature is about 65 °C.
In some embodiments, the temperature for incubating, culturing, or assaying components of the secretory compositions/cocktails may be performed for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, or 14 days.
In some embodiments, the media may comprise oatmeal, water, yeast, glucose, cellulose, and Czapek' s agar. In some embodiments, the media may be supplemented with an antibiotic selected from the group consisting of penicillin-G, ampicillin, streptomycin. In some embodiments, the media may be supplemented with reagent to allow for color detection, such as methyl green. In some embodiments, the media may be supplemented to enhance the production of specific enzymes, such as DNA to encourage the production on DNAses, or whole cells or components of bacterial or viral species to encourage enzymes that inhibit or kill pathogens.
In some embodiments, the pH may be about 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 and ±0.01, ±0.02, ±0.03, ±0.04, ±0.05, ±0.06, ±0.07, ±0.08, ±0.09, ±0.1, ±0.2, ±0.3, ±0.4, ±0.5, ±0.6, ±0.7, ±0.8, or ±0.9. In certain embodiments, the invention relates to any one of the above- mentioned methods, wherein the pH is between about 5 and about 9. In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the pH is between about 6 and about 8. In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the pH is about 5, about 6, about 7, about 8, or about 9. In certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the pH is about 6, about 7, or about 8. In
certain embodiments, the invention relates to any one of the above-mentioned methods, wherein the pH is about 7.
In some embodiments, the media may be enriched with nucleic acids, sugars, carbohydrates, fatty acids and lipids, DNA, deoxyribose, proteinase K, lysozyme (e.g., phi29 lysozyme) or antimicrobial chemicals or peptides (e.g. microsilver, antibiotics, or ampD from Bacillus species such as Bacillus cereus E33L) during the incubating, culturing, purification, assaying, or other production steps. In some embodiments, enzymes that digest bacterial cell walls including glycan strand-cleaving enzymes (glycosidases) including N- acetylglucosaminidases, lysozymes and lytic transglycosylases. These include the N- acetylmuramyl-L-alanine amidases and peptidoglycan endopeptidases (Vollmer et al, 2008).
In some embodiments, me amount of DNA, RNA, deoxyribose or other nucleic acids, added may be 0.1, 0.2, 0.3, 0.4, 0.5. 0.6, 0.7, 0.8, 0.9, or 1.0 g. Such enrichment may increase potency of the isolated fungal species and/or any of the components of the secretory compositions/cocktails. In some embodiments, the culture may be
supplemented with Na+, K+, Mg++, or Ca++. In some embodiments, the ratio of the Mg++ to Ca++ or Na+ to K+ may be 1:1, 1:2, 2:1, 1:3, 3:1, 1:4, 4:1, 1:5, 5:1, 1:6, 6:1, 1:7, 7:1, 1:8, 8:1, 1:9, 9:1, 1:10, or 10:1. For example, addition of Ca++ may prolong the survival and activity of certain enzymes (i.e., Ca2+ protects DNAses against digestion by proteases), whereas no Ca** leads to a shortened lifespan of certain enzymes (due to diminished protection against digestion by proteases).
Modifications of the Ca++ concentrations and/or ratios of the [ Ca++] to [Mg ++ ] can prolong or shorten the life of enzymes within the extract.
In some embodiments, the fungal culture is subject to agitated growth, static growth, or altering static and agitated growth. In some embodiments, the agitation is at 50 rpm, 75 rpm, 100 rpm, 125 rpm, 150 rpm, 175 rpm, or 200 rpm. In some embodiments, the fungal culture is subject to continuous culture or non-continuous culture.
In some embodiments, the lighting conditions are varied to encourage spore formation, including prolonging or shortening duration of exposure to light for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours.
In some embodiments, the sample used as source for fungal species may
comprise compost. In some embodiments, the sample may be incubated on yeast protein soluble starch agar plates comprising yeast extract, K2HPO4, MgSCU, soluble starch, and a pH about 7, among others. In some embodiments, antibiotics selected from the group consisting of polymyxin B, penicillin G, ampicillin, and streptomycin may be added at 5 ppm, 10 ppm, 15 ppm, 20 ppm, 25 ppm, 30 ppm, 35 ppm, 40 ppm, 45 ppm, or 50 ppm.
///. Extremophilic Funeal Species
Extremophilic fungal species identified, isolated, and characterized by the methods set forth herein may encompass fungal species homologous to known thermophilic, psychrophilic, and mesophilic fungi. In one embodiment, the novel, extremophilic fungal species is described in Example 1, and characterized by the bacterial properties set forth in Example 2.
Extremophilic fungi and other extremophilic organisms such as extremophilic bacteria may be useful in process applications in biotechnology, such as the methods of the present invention, stemming from their ability to grow at relatively high temperatures with attendant high metabolic rates, production of physically and chemically stable enzymes, and elevated yields of end products. In some cases, the extremophilic fungus is TM-417. Other thermophilic fungal species may include, but not limited to, Zygomycetes, Absidia corymbifera, Mortierella turftcola, Mwolfi, Mucormiehei, Mpusillus, Rhizomucor sp., Rhizopus arrhizus, Chaetomium sp., R. cohnii, R. microspores, Ascomycetes, Allescheria terrestris, Byssochlamys verrucosa, Chaetomium britannicum, C. thermophile, C.
thermophile var. coprophile, C. thermophile var. dissitum, C. virginicum, Emericella nidulans, Hansenula polymorpha, Myriococcum albomyces, Sphaerospora saccata, Talaromyces byssochlamydoides, Temersonii, T leycettanus, T thermophiles,
Thermoascus aurantiacus, T crustaceus, Thielavia australiensis, T sepedonium, T thermophile, Basidiomycetes, Coprinus delicatulus, Mycelia Sterila, Burgoa- Papulaspora, Papulaspora thermophile, Deuteromycetes, Acremonium albamensis, Acrophialophora fusispora, Aspergillus candidus, A. fumigatus, Botrytis sp.,
Sphaerospora saccata, Calcarisporium thermophile, Cephalosporium sp., Allescheria terrestris, Cephalosporium sp., Thielavia australiensis, Geotrichum sp. A, Humicola grisea var. thermoidea. H. insolens. H. lanuginose, H. stellate, Malbranchea pulchetta var. suljurea, Nodulisporium cylindroconium, Tritirachium sp. A, Paecilomyces crustaceus, Thermoascus, P. puntonii, P. variotii, Paecilomyces sp., Byssochlamys
verrucosa, Paecilomyces sp., Talaromyces byssochlamydoides, Penicillium duponti Talaromyces thermophilus, P. emersonii Talaromyces, P. leycettanum Talaromyces, P. piceum, P. argillaceum, Ptychogaster sp., Sporotrichum pulverulentum, Scolecobasidium sp. A, Diplorhinotrichum galloparum, Sporotrichum thermophile, Thielavia, S.
pulverulentum, Stilbella thermophile, Thermomyces ibadanesis, Torula thermophile, Torulopsis Candida, Tritirachium sp. A, and Nodulisporium cylindroconium.
In certain embodiments, the fungal species may be 60%, 65%, 70%,75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homologous to any of the aforementioned mentioned thermophilic and mesophilic fungi. In some embodiment, the fungal species may be 60%, 65%,
70%,75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homologous to any of the following Clostridium thermocellum. Clostridium cellulolyticum, Thermoanaerobacterium saccharolyticum, Clostridium stercorarium, Clostridium stercorarium 11, Caldiscellulosiruptor kristjanssonii, and Clostridium phytofermentans; Thermoanaerobacterium
thermosulfurigenes, Thermoanaerobacterium aotearoense, Thermoanaerobacterium polysaccharolyticum, Thermoanaerobacterium zeae, Thermoanaerobacterium xylanolyticum, Thermoanaerobacterium saccharolyticum, Thermoanaerobium brockii, Thermoanaerobacterium thermosaccharolyticum. Thermoanaerobacter
thermohydrosulfuricus, Thermoanaerobacter ethanolicus, Thermoanaerobacter brocki, Clostridium thermocellum, Clostridium cellulolyticum, Clostridium phytofermentans, Clostridium straminosolvens, Geobacillus thermoglucosidasius, Geobacillus stearothermophilus, Saccharococcus caldoxylosilyticus, Saccharoccus thermophilus, Paenibacillus campinasensis, Bacillus flavothermus, Anoxybacillus kamchatkensis, Anoxybacillus gonensis, Caldicellulosiruptoracetigenus, Caldicellulosiruptor saccharolyticus, Caldicellulosiruptor kristjanssonii, Caldicellulosiruptor owensensis, Caldicellulosiruptor lactoaceticus, Anaerocellum thermophilum, or Chaetomium cellulolyticum.
Major groups of thermophilic bacteria include eubacteria and archaebacteria.
Thermophilic eubacteria include: phototropic bacteria, such as cyanobacteria, purple bacteria, and green bacteria; Gram-positive bacteria, such as Bacillus, Clostridium, Lactic acid bacteria, and Actinomyces; and other eubacteria, such as Thiobacillus, Spirochete,
Desulfotomaculum, Gram-negative aerobes, Gram-negative anaerobes, and Thermotoga. Within archaebacteria are considered Methanogens, extreme thermophiles (an art- recognized term), and Thermoplasma. In some embodiments, the invention relates to identifying, characterizing, and isolating extremophilic bacteria related to or homologous to Gram-negative organotrophic thermophiles of the genera Thermits, Gram-positive eubacteria, such as genera Clostridium, and also which comprise both rods and cocci, genera in group of eubacteria, such as Thermosipho and Thermotoga, genera of
Archaebacteria, such as Thermococcus, Thermoproteus (rod-shaped), Thermqfilum (rod- shaped), Pyrodictium, Acidiamis, Sulfolobus, Pyrobaculum, Pyrococcus, Thermodiscus, Staphylothermus, Desulfurococcus, Archaeoglobus, andMethanopyrus. In some embodiments, the invention relates to identifying, characterizing, and isolating extremophilic bacteriarelated to or homologous to thermophilic fungus including, but are not limited to: Clostridium thermosulfurogenes, Clostridium cellulolyticum, Clostridium thermocellum, Clostridium thermohydrosulfuricum, Clostridium thermoaceticum, Clostridium thermosaccharolyticum, Clostridium tartarivorum, Clostridium
Ihermocellulaseum, Clostridium phytofermentans, Clostridium straminosolvens, Thermoanaerobacterium thermosaccarolytictan, Thermoanaerobacterium
saccharolyticum, Thermobacteroides acetoethylicus, Thermoanaerobium brockii, Methanobacterium thermoautotrophicum, Anaerocellum thermophilium, Pyrodictium occultum, Thermoproteus neuirophilus, Thermqfilum librum, Thermothrix thioparus, Desulfovibrio thermophilus, Thermoplasma acidophilum,Hydrogenomonas
thermophilus, Thermomicrobium roseum, Thermus flavas, Thermits ruber, Pyrococcus furiosus, Thermus aquaticus, Thermus thermophilus, Chloroflexusaurantiacus, Thermococcus litoralis, Pyrodictium abyssi, Bacillus stearothermophilus, Cyanidium caldarium, Mastigocladus laminosus, Chlamydothrix calidissima, Chlamydothrix penicillata, Thiothrix carnea, Phormidium tenuissimum, Phormidium geysericola. Phormidium subterraneum, Phormidium bijahensi, Oscillatoria filiformis,
Synechococcus lividus, Chlorqflexus aurantiacus, Pyrodictium brockii, Thiobacillus thiooxidans, Sulfolobus acidocaldarius, Thiobacillus thermophilica, Bacillus stearothermophilus, Cercosulcifer hamathensis, Vahlkampfia reichi, Cyclidium citrtdlus, Dactylaria gallopava, Synechococcus lividus, Synechococcus elongatus, Synechococcus minervae, Synechocystis aquatilus, Aphanocapsa thermalis, Oscillatoria
terebriformis, Oscillatoria amphibia, Oscillatoria germinata, Oscillatoria okenii, Phormidium laminosum, Phormidium parparasiens, Symploca thermalis. Bacillus acidocaldarias, Bacillus coagulans, Bacillus thermocatenalatus, Bacillus licheniformis, Bacillus pamilas, Bacillus macerans, Bacillus circulans, Bacillus laterosporus, Bacillus brevis, Bacillus subtilis, Bacillus sphaericus, De sulfa tomacuhim nigrificans,
Streptococcus thermophilus, Lactobacillus thermophilus, Lactobacillus bulgaricus, Bifidobacterium thermophilum, Streptomyces firagmentosporus, Streptomyces thermonitrificans, Streptomyces thermovulgaris, Pseudonocardia thermophila,
Thermoactinomyces vulgaris, Thermoactinomyces sacchari, Thermoaclinomyces Candidas, Thermomonospora curvata, Thermomonospora viridis, Thermomonospora citrina, Microbispora thermodiastatica, Microbispora aerata, Microbispora bispora, Actinobifida dichotomica, Actinobifida chromogena, Micropolysporacaesia,
Micropolyspora fiteni, Micropolyspora cectivugida, Micropolyspora cabrobrunea, Micropolyspora thermovirida, Micropolyspora viridinigra, Methanobacterium thermoautothropicum, Caldicellulosiruptor acetigenus, Caldicellulosiruptor saccharolyticus, Caldicellulosiruptor kristjanssonii. Caldicellulosiruptor owensensis, Caldicellulosiruptor lactoaceticus, variants thereof, or progeny thereof.
In certain embodiments, the invention relates to a method of identifying, characterizing, and isolating extremophilic bacteria related or homologous to the genera Thermoanaerobacterium or Thermoanaerobacter, including, but not limited to, species selected from the group consisting of: Thermoanaerobacterium thermosulfurigenes, Thermoanaerobacterium aotearoense, Thermoanaerobacterium polysaccharolyticum, Thermoanaerobacterium zeae, Thermoanaerobacterium xylanolyticum,
Thermoanaerobacterium saccharolyticum, Thermoanaerobium brockii,
Thermoanaerobacterium thermosaccharolyticum, Thermoanaerobacter
thermohydrosulfiiricus, Thermoanaerobacter ethanolicus, Thermoanaerobacter brockii. variants thereof, and progeny thereof.
In certain embodiments, the invention relates to a method of identifying, characterizing, and isolating extremophilic bacteria related to or homologous to the genera Geobacillus. Saccharococcus, Paenibacillus, Bacillus, and Anoxybacillus, including, but not limited to, species selected from the group consisting of: Geobacillus thermoglucosidasius, Geobacillus stearothermophilus, Saccharococcus
caldoxylosilytieus, Saccharoccus thermophilus, Paenibacillus campinasensis, Bacillus flavolhermus, Anoxybacillus kamchatkensis, Anoxybacillus gonensis. variants thereof, and progeny thereof.
In certain embodiments, the invention relates to a method of identifying, characterizing, and isolating extremophilic bacteria related to or homologous to the genera selected from the group consisting of Saccharophagus degradans;
Flavobacterium johnsoniae; Fibrobacter succinogenes; Clostridium hungatei;
Clostridium phytofermentans; Clostridium cellulolyticum; Clostridium aldrichii;
Clostridium termitididis; Acetivibrio cellulolyticus; Acetivibrio ethanolgignens;
Acetivibrio multivorans; Bacteroides cellulosolvens; and Alkalibacter
saccharqfomentans, variants thereof and progeny thereof.
IV. Recombinant Extremophilic Fungal species or Recombinant Expression of
Fungal Genes.
In one embodiment, the invention relates to recombinant, extremophilic fungal species, wherein the isolated novel extremophilic fungus is genetically-modified. These can be prepared by deleting or inactivating one or more genes, or adding novel genes from other species, optionally followed by a growth-based selection for mutants with improved performance or potency for producing enzymes and other antimicrobial molecules, such as proteases, lipases, glycan strand-cleaving enzymes (glycosidases), antimicrobial peptides, and cellulases. In certain embodiments, the genetically- modified extremophilic fungal species is modified to produce enzymes known to inhibit the growth or kill microbial species (e.g. ampD, lysozymes such as phi29 lysozyme). These proteins may be enhanced by adding bacterial targeting peptides that bind the enzymes to the cell surface of targeted organisms. In other
embodiments, the genetically-modified extremophilic fungal species used in the methods of the invention can be cultured using any of the aforementioned conditions set forth in herein. In some embodiments, the genetically modified/recombinant extremophilic fungal species can be selected by a growth-based procedure to produce enzymes most efficiently at certain conditions (variations, in pH, temperature, light, CO2, O2, salt, nutrient, Ca** levels, nutrient, growth factors, proteinase K, lysozyme such as phi29 lysozyme). In certain embodiments, the genetically-modified extremophilic fungal species used in the methods of the invention can be selected by
a growth-based procedure to produce enzymes most efficiently at about 45 °C, 50 °C, 55 °C, 60 °C, or 65 °C. In certain embodiments, the genetically-modified extremophilic fungal species used in the methods of the invention can be selected by a growth-based procedure to produce enzyme most efficiently at a certain pH. In certain embodiments, the genetically-modified microorganisms used in the methods of the invention can be selected by a growth-based procedure to produce enzyme most efficiently at about pH 7.
In certain embodiments, the recombinant extremophilic fungal species may comprise at least one heterologous gene, wherein said heterologous gene is expressed at sufficient levels to increase the ability of said recombinant
extremophilic fungal species to enhance production or potency of secreting enzymes or to confer upon said recombinant microorganism (which may be thermophilic) the ability to enhance production or potency of secreting enzymes. In some
embodiments, the recombinant extremophilic fungal species may comprise at least two, three, four or five heterologous genes.
In another embodiment, genes from the extremophilic fungal species may be isolated and introduced into other species for protein production using the native sequence, or with improved properties though genetic modification. These improvements may include improved codon usage and expression levels, improved secretion, targeting peptides, increased activity, increased stability. Organisms that may be used for expression include yeasts (e.g. Saccharomyces cerevisiae and Pichia pastoris), bacteria (e.g. E. coli) and insect cells (e.g. baculovirus protein expression systems).
V. Secretory Compositions/Cocktails Derived from Fungal Species
Novel, extremophilic fungal species identified, characterized, and isolated according the methods of the present invention have a variety of growth characteristics that can be exploited to provide a unique combination of enzymes, heat-resistant lipases, proteases, RNases and DNases that destroy biological material within minutes upon contact. Secretory compositions/cocktails derived from fungal species may be purified from cultures which can be grown in broth comprising yeast extract, K2HPO4, MgSO-i, soluble starch, methyl green, DNA salmon sperm; agar, and adjusted to pH 7.3. Cell mass may be removed from the sample comprising secretory compositions/cocktails by
vacuum filtration through coarse filter paper (such as Fisherbrand Filter Paper P8). The cell mass may also be lysed and used for the production of enzymes that are not secreted. The filtrate may be filtered under vacuum through medium (Fisherbrand Filter Paper PS), and men through fine filter paper (Fisherbrand Filter Paper P2). The filtered sample may comprise a mixture of crude enzymes. To inhibit any bacterial and/or fungal growth, 0.02% sodium azide may be added to the crude enzyme sample. All crude enzyme samples may be stored at ambient temperature. In some embodiments, the crude enzyme samples comprising secretory compositions/cocktails may be dried or freeze- dried. In some embodiments, the dried secretory compositions/cocktails may be reconstituted prior to use.
In some embodiments, the secretory compositions/cocktails may be protected in microspheres. Such embodiments, may comprise balls of chitin, which are digested slowly by lysozyme.
In some embodiments, additional purification and/or concentration steps may be performed on the secretory compositions/cocktails. For example, such steps may comprise membrane preparation (e.g., using 47mm, 0.2um FP-Vericel membrane, membrane filtration unit under vacuum, ultrafiltration membrane concentration, dialysis, pressure cell (e.g., via Ami con pressure cell), cellulose membrane (e.g., having a 1 kDa, 2 kDa, 3 kDa, 4 kDa, 5 kDa, 10 kDa, 15k Da, 20 kDa cutoff), sephadex column chromatography, and affinity membrane purification (e.g. DNA coated membrane), or combinations thereof. Such steps may also include the use of tangential flow systems with polyethersulfone and/or Composite Regenerated Cellulose membranes/filters (e.g. thePellicon system, Millipore). Such combinations of purification, filtration, concentration, dialysis steps may lead to a 25-, 30-, 35-, 40-, 45-, 50-, 55-, 60-, 65-, 70-, 75-, 80-, 85-, 90-, 95-, 100-, 105-, 110-, 115-, 120-, 125-, 130-, 135-, 140-, 145-, 150-, 155-, 160-, 165-, 170-, 175-, 180-, 185-, 190-, 195-, or 200-fold increase in specific activity, with 25% ±5, ±10, or ±15 of the initial enzyme activity. In some embodiments, the secretory
compositions/cocktails may be concentrated directed from the media, i.e., crude sample. In some embodiments, the secretory compositions/cocktails may be 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% pure of the desired enzyme.
Secretory compositions/cocktails derived from fungal species as provided herein may comprising any of the following enzymes, proteases, and the like, alone or in any
combination, including, but not limited to, urease, DNase, RNase, exonuclease, endonuclease, ribonuclease, chitinase, amylase, acetoin reductase, an indole-3-acetamide hydrolase, a tryptophan monooxygenase, an acetolactate synthetase, an a-acetolactate decarboxylase, a pyruvate decarboxylase, a diacetyl reductase, a butanediol
dehydrogenase, an aminotransferase, a tryptophan decarboxylase, an amine oxidase, an indole-3 -pyruvate decarboxylase, an indole-3- acetaldehyde dehydrogenase, atryptophan side chain oxidase, anitrile hydrolase, anitrilase, a peptidase, a protease, an adenosine phosphate isopenteny .transferase, a phosphatase, an adenosine kinase, an adenine phosphoribosyltransferase, CYF735A, a 5'ribonucleotide phosphohydrolase, an adenosine nucleosidase, a zeatin cis-trans isomerase, a zeatin O-glucosyltransferase, a β- glucosidase, a cis-hydroxylase, a CK cis-hydroxylase, a CK N- glucosyltransferase, a 2,5-ribonucleotide phosphohydrolase, an adenosine nucleosidase, a purine nucleoside phosphorylase, a zeatin reductase, ahydroxylamine reductase, a2-oxoglutarate dioxygenase, agibberellic 2B/3B hydrolase, agibberellin 3-oxidase, agjbberellin 20- oxidase, a chitosanase, a chitinase, a p-l,3-glucanase, a P-l,4-glucanase, a β-1,6- glucanase, an aminocyclopropane-l-carboxylic acid deaminase, chitosanase, a cellulase, a lipase, a lignin oxidase, a protease, a glycoside hydrolase, a phosphatase, a nitrogenase, a nuclease, an amidase, a nitrate reductase, a nitrite reductase, an amylase, an ammonia oxidase, aligninase, a glucosidase, a phospholipase, a phytase, apectinase, a glucanase, a sulfatase, a urease, a xylanase, an endocellulase, an exocellulase, a β-glucosidase, phospholipase, acetate kinase, phosphotransacetylase, lactate dehydrogenase, pyruvate decarboxylase (PDC), alcohol dehydrogenase (ADH), xylose isomerase, xylulokinase, L- arabinose isomerase, orL-ribulose-5-phosphate 4-epimerase, glycan strand-cleaving enzymes (glycosidases) including N- acetylglucosaminidases, acetylmuramyl-L-alanine amidases, lysozymes, lytic transglycosylases, and peptidoglycan endopeptidases. The specific activity of any of the aforementioned enzymes, proteases, and the like, may be assayed using methods known in the art.
VI. Applications/Uses
One aspect of the invention relates to a method utilizing any one of the above- mentioned extremophilic fungal species or genetically-modified/recombinant extremophilic fungal species to produce certain secretory compositions/cocktails most efficiently under appropriate culture, incubation, or assay conditions. Such secretory
compositions/cocktails may be useful in a variety of bioprocess, cleaning/sterilization, industrial, agricultural, and pharmaceutical/medical and commercial application, household applications set forth herein. Exemplary applications/uses of the secretory compositions/cocktails are provided below.
A. CAeaning'sterilizationCompositions
One aspect of the invention relates to use of the secretory compositions/cocktails described herein as cleaning/sterilization compositions.
As used herein, "affected surface" means that the surface is at least partially covered by contamination, including microorganism contamination, e.g., biofilm, yeast, viral, fungal, bacterial, protein, extracellular matrices, and the like, or is a surface prone to developing a biofilm, bacteria, and the like, thereon (e.g., is present in an aqueous or moist environment where contamination has formed in the past) or is a surface where prevention of contamination is desired (e.g., is present in an aqueous or moist environment). "Removing" can include removing all or a portion of the contamination as well as reducing the thickness of contamination by successively removing layers of organisms, thereby exposing additional contamination layer(s) below. Once removed from the affected surface, the detached contamination can be rinsed away, flushed, or otherwise transported from the affected environment (e.g., water system).
Treatment of a surface or other substrate can reduce the amount of contaminating microorganisms on the substrate. Such treatment can reduce the amount of
microorganisms on the substrate by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, or 100%. Treatment of a surface or other substrate can reduce the activity of contaminating microorganisms on the substrate. Such treatment can reduce the activity of
microorganisms on the substrate by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, or 100%. Activity can include but is not limited to pathogenicity, viability, reproduction, metabolism, toxin production, or other activity.
The compositions can be used to prevent the buildup of contamination on a surface, especially a surface prone to contamination formation. As used herein,
"preventing" means prophylactically inhibiting the formation or re-formation of contamination on a surface. Preventing can include permanent or temporary cessation of
contamination formation, as well as retardation or slowing of growth of biofilm, bacteria, or the like.
Thus, one aspect of the invention relates to method for treating a biofilm-affected surface, comprising the step of contacting the affected surface with an effective amount of any of the aforementioned secretory compositions/cocktails. The secretory
compositions/cocktails can effectively penetrate through the biofilm layers, including the matrix, to successfully reach the surface underneath to disrupt the biofilm's attachment sites.
In some embodiments, an affected surface may be part of an industrial, marine, or household environment. In some embodiment, an affected surface may be selected from the group consisting of cooling water systems, heat exchangers, pulp and paper manufacturing, food processing systems, metal working, photo processing, reverse osmosis membranes, water processing, flow channels, turbines, solar panels, pressurized water reactors, injection and spray nozzles, steam generators, process equipment, secondary oil recovery injection wells, and piping. In some embodiment, an affected surface may be a marine system selected from the group consisting of pipelines, oil-rigs, and boat hulls. In some embodiment, an affected surface is a household system selected from the group consisting of swimming pools, toilets, household drains, cutting surfaces, sinks, urinals, counter-tops, shower and bam surfaces, vases, petfood or water bowls, decorative water landscaping, and bird baths. In some embodiments, an affected surface comprises a material selected from the group consisting of metal, stainless steel, plastic, ceramic, porcelain, rubber, wood, concrete, cement, rock, marble, gypsum, and glass. In some embodiment, the step of contacting includes pouring, spraying, applying, squirting, dosing, dipping, cleaning, soaking, dousing, washing, covering, misting, scattering, spreading, flushing, injecting, incorporating, or spraying.
For example, planktonic microbes (e.g., bacteria, fungi) can adhere to virtually all natural and synthetic surfaces, with many of such microbes forming permanent attachments. It is commonly believed that microbes prefer to live as sessile organisms rather than in planktonic form because life in a sessile state facilitates development of unique survival mechanisms not found in their planktonic counterparts. Generally recognized as the first step in biofilm formation, microbial adhesion stimulates the production of extracellular matrix polymers, colloquially referred to as "slime" due to
their slimy feel and appearance. This matrix further strengthens adhesion, provides protection to the sessile microbial population, and facilitates recruitment and growth of additional microbes to the biofilm community.
As the biofilm matures, successive microbe layers are added on top of one another, forming a multi-layered microbial system. A biofilm may comprise a vast number of different microorganism types or may include a specific microorganism as the predominant microbe. Biofilms also commonly include various abiotic materials (e.g., rust, dirt) mat have become embedded in the biofilm matrix. Common biofilms found in industrial and household settings include those colonized by organisms selected from the bacterial genera Pseudomonas, Staphylococcus, Aeromonas, and Klebsiella, the family Enterobacteriaceae (including, e.g., Escherichia coli), and the fungi genera Aspergillus, Penicillium, Myceliophthora, Humicola, Irpex, Fusarium, Stachybotrys, Scopulariopsis, Chaetomium, Mycogone, Verticillium. Myrothecium. Papulospora. Gliocladium, Cephalosporium, Acremomum, and combinations thereof.
Biofilms are extremely complex microbial ecosystems. When colonized into a biofilm, the behavior, structure, and physiology of microbes change dramatically, resulting in a number of potential advantages not possessed by the free-floating, planktonic form. Because of their enhanced survival mechanisms, biofilms can quickly respond and adapt to changing internal and external conditions, making their removal and prevention especially difficult. Biofilm structure and the physiological attributes of microorganisms within the biofilm also provide an intrinsic tolerance to antimicrobial agents (e.g., antibiotics, disinfectants, germicides, antifungals). When biofilm is removed from a surface via traditional means, such as by vigorous mechanical scrubbing with an industrial cleaner and/or disinfectants, a few "persister" cells, which are metabolically equipped to survive in especially hostile environments, still typically remain behind on the surface. These persister cells "re-seed" the surface, triggering biofilm re-growth. Repeated cycles of biofilm removal and re-growth typically result in increasingly aggressive re-colonization by increasingly robust microbes.
As a result, biofilm control is especially difficult. However, the secretory compositions/cocktails described herein may be strong enough not only to kill the wide variety of robust microbes present, but also to effectively reach the surface underneath the biofilm such that the biofilm material is completely detached from the surface and
can thus be removed (e.g., flushed) from the system. The cleaning compositions comprising secretory cocktails described herein are capable of penetrating and disrupting the biofilm matrix.
Typical surfaces can include those selected from the group consisting of metal, stainless steel, plastic, ceramic, porcelain, rubber, wood, concrete, cement, rock, marble, gypsum, and glass. The secretory composition/cocktails can contact the affected surface by any suitable means, such as lavage (e.g., washing with repeated injections of solution), misting, spraying, diluting, mopping, pouring, dipping, soaking, and combinations thereof. Contacting can be followed by removing detached debris from the system.
Removing debris can be accomplished by any suitable means, including flushing, rinsing, draining, lavage, misting, spraying, mopping, wiping, rinsing, dipping, and combinations thereof, for example with a clean liquid such as water.
Acute infectious gastroenteritis is an extremely common illness, second in frequency only to acute respiratory illness among families (New Engl J Med (2007) 357;11). Although it had long been suspected that such illnesses were caused by viruses, it was only after clinical and laboratory studies were carried out over the past three decades that causative viruses were identified. Among the most prominent are a novel group of viruses originally referred to as Norwalk-like agents - named after Norwalk, Ohio, where an outbreak of illness was caused by the prototype agent - and now called noroviruses. The biologic, physicochemical, and epidemiologic features of noroviruses present a serious challenge for infection control. Noroviruses are extremely infectious, and as few as 10 to 100 particles may be needed to cause infection. These viruses also are highly resistant to inactivation by freezing, heating to 60°C, exposure to chlorine in concentrations of 0.5 to 1.0 mg per liter, pH levels of 2.7, and treatment with ether, ethanol, or detergent-based cleaners. Thus, steaming or depuration of shellfish does not entirely eliminate the risk of transmission. Effective surface decontamination can be accomplished with solutions containing hypochlorite at 5000 ppm.
The primary control measures for norovirus outbreaks are environmental decontamination, prevention of contamination of water and food supplies (including restriction of the activity of sick food handlers), and possibly cohorting of infected patients in health care facilities or on cruise ships.
Surfaces that can be affected by biofilms or otherwise contaminated by disease
causing agents can include those found in a variety of systems, such as those of the industrial, rail, marine, aerial, and household environments. Industrial systems can include those such as cooling water systems, heat exchangers, pulp and paper manufacturing, food processing systems, metalworking, photo processing, reverse osmosis membranes, water processing, flow channels, turbines, solar panels, pressurized water reactors, injection and spray nozzles, steam generators, process equipment, secondary oil recovery injection wells, and piping (e.g., drinking water).
Marine systems can include pipelines (e.g., of the offshore oil and gas industry), off-shore oil- rigs, and boat hulls. Marine-related environments include ship hallways and other public areas, air filters, air conditioning units, bathrooms, bedrooms and galleys. Aerial-related environments include air filters, air conditioning units, seats, and bathrooms of airplanes and airports.
Household systems include those surfaces found in swimming pools, toilets, household drains, and other household surfaces such as cutting surfaces, sinks, counter- tops, shower and bath surfaces, vases, pet food or water bowls, decorative water landscaping (e.g., fountains, ponds), and bird baths.
The concentration and amount of cleaning composition that is required to effectively treat and/or prevent biofilm or contamination in any particular situation will depend upon factors such as the specific alkali surfactant used, the level of biofilm or contamination, the level of treatment desired, the type of surface to be treated (e.g., household, various industrial settings), and length of time the cleaning composition will be in contact with the affected surface, all of which can be determined by one skilled in the art in view of this disclosure. Thus, it can be said that the amount of secretory composition/cocktail needed for any given surface will be an "effective amount". As used herein, an "effective amount" is the amount (i.e., concentration, quantity) of secretory composition/cocktail needed to achieve the desired level of treatment for a particular set of conditions. An effective amount may comprise decontaminating the affected surfaces up to 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of bacteria, fungal, biofilm, or viral growth. The composition/cocktail may be applied at different temperatures for different levels of activity, e.g. 15 °C, 20 °C, 30 °C, 40 °C, 50 °Cor60 °C.
The cleaning composition can be in any suitable form. For example, product
forms can include those such as detergents, powders (e.g., lyophilized powders), liquids, gels, pastes, and suspensions, as well as concentrates. Products or concentrates of such can be contained and deployed (e.g., dispensed and deposited upon a surface) with a variety of containers, vessels, tanks, or packages ranging from small (e.g. for household use) to large dose volumes (e.g., for industrial cleaning), wherein said containers can be re-usable (e.g., plant tanks) to disposable (e.g., a small bottle or pouch). The container can contain enough product for a single use event or for multiple uses. The cleaning composition can be a fully-formulated ready-for-use product, or can require preparation before use. For example, the composition can be in the form of a kit comprising composition ingredients and instructions for preparation, or can be a concentrate for dilution either within or outside the container.
The cleaning compositions can optionally include any suitable adjunct ingredients, such as those known in the art for use in such cleaning compositions or washing detergents. For example, adjuncts can include, but are not limited to colorants and fragrances.
B. Agricultural medical, manufacturing, and environmental products
Bacterial, yeast, viral, or fungal contamination of clinical, agricultural,
manufacturing, or environmental products may lead to severe illness, and even death, if contacted by a subject or administered to a subject. Thus, in one aspect of the invention, the secretory compositions/cocktails of the present invention could be used to sterilize or decontaminate medical devices (such as catheters, surgical tools, stents, IVs), agricultural specimens (such as food, water supply, waste water, sludge, egg shells, plants, seeds, food containers), environmental specimens (such as lakes, and pools), and manufacturing samples (such as the machinery for processing samples). Non-limiting examples of manufacturing samples may also include sterile products and their components and intermediates that are manufactured for medical uses. In some embodiments, the secretory compositions/cocktails of the present invention could be used to sterilize wound dressings in remote or field locations. Other embodiments address increasing safety concerns to decontaminate both food products and the water supply from fungal, bacterial or viral contamination. Thus, the secretory compositions/cocktails may also apply to recreational facilities such as swimming pools and lakes, which may be contaminated with high levels of potentially pathogenic organisms or organisms that produce undesirable odors.
Another aspect of the invention relates to a method of breaking down urea comprising the step of contacting an agricultural, medical, manufacturing, and environmental product with an effective amount of any of the aforementioned secretory
compositions/cocktails of the present invention. Such methods are based in part on the properties of the extremophilic fungi of the present invention to secrete ureases, which would help break down urea in farms and public places that have a lot of urine and/or feces. In some embodiments, the secretory compositions/cocktails of the present invention could be engineered to use ammonia and prevent the bad smells from urine and/or feces. In some embodiments, the secretory compositions/cocktails of the present invention could be used for fertilizer wastewaters. In some embodiments, the secretory compositions/cocktails of the present invention could be used for pH control and as a source of ammonia and carbon dioxide.
C Biomass and Biofuels
Another aspect of the invention relates to a method of producing biofuels comprising the step of contacting a biomass with an effective amount of any of the aforementioned secretory compositions/cocktails of the present invention. In some embodiments, the biofuel may comprise alcohol, ethanol, biodiesel, bioethanol, bioalcohol, green diesel, biofuel gasoline, vegetable oil, biogas, syngas, solid biofuels, and the like. In anon-limiting example, the biomass can include, but is not limited to, lignocellulosic material woody biomass, such as recycled wood pulp fiber, sawdust, hardwood, softwood, algae, corn, sugarcane, sweet sorghum, trees, and combinations thereof; grasses, such as switch grass, cord grass, rye grass, reed canary grass, miscanthus, or a combination thereof; sugar-processing residues, such as but not limited to sugar cane bagasse; agricultural wastes, such as but not limited to rice straw, rice hulls, barley straw, corn cobs, cereal straw, wheat straw, canola straw, oat straw, oat hulls, and corn fiber; stover, such as but not limited to soybean stover, corn stover; and forestry wastes, such as but not limited to recycled wood pulp fiber, sawdust, hardwood (e.g., poplar, oak, maple, birch, willow), softwood, or any combination thereof. Other biomass includes agricultural wastes, such as manure, wastewater, cereal straws, including wheat straw, barley straw, canola straw and oat straw; com fiber; stovers, such as com stover and soybean stover; grasses, such as switch grass, reed canary grass, cord grass, and miscanthus; or combinations thereof.
In some embodiments, paper sludge is also a viable biomass for biofuel production. Paper sludge is solid residue arising from pulping and paper-making, and is typically removed from process wastewater in a primary clarifier. The cost of disposing of wet sludge is a significant incentive to convert the material for other uses, such as conversion to ethanol. Methods provided by the present invention are widely applicable. Moreover, the saccharification and/or fermentation products may be used to produce ethanol or higher value added chemicals, such as organic acids, aromatics, esters, acetone and polymer intermediates.
In other embodiment, the present invention relates to methods for biomass into ethanol, wherein said biomass is selected from the group consisting of grass, switch grass, cord grass, rye grass, reed canary grass, mixed prairie grass, miscanthus, sugar- processing residues, sugarcane bagasse, sugarcane straw, agricultural wastes, rice straw, rice hulls, barley straw, corn cobs, cereal straw, wheat straw, canola straw, oat straw, oat hulls, corn fiber, stover, soybean stover, corn stover, forestry wastes, recycled wood pulp fiber, paper sludge, sawdust, hardwood, softwood, and combinations thereof.
D. Pharmaceutical/medical uses
Another aspect of the invention, relates to a method for treating a wound comprising the step of contacting the surface of the injured area with an effective amount of any of the aforementioned secretory compositions/cocktails. In some embodiments, the injured area is a cut, abrasion, open wound, sore, or abscess.
Another aspect of the invention, relates to a method for treating a skin or nail disorder comprising the step of contacting the affected surface of the skin or nail with an effective amount of any of the aforementioned secretory compositions/cocktails. In some embodiments, the skin or nail disorder is selected from the group consisting of acne, actinic keratosis, alopecia areata, athlete's foot, onchomychosis, atopic dermatitis, osmidrosis, eczema, fungal infection of the nails, psoriasis, rosacea, slow wound healing, folliculitis, keratosis pilaris, perioral dermatitis, angiofibromas, cutaneous inflammation, aging damage, dyschromia, premature greying hair, and seborrhea.
The secretory compositions/cocktails of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for topical application, for example, as a cream, lotion, ointment, foam, or a controlled-release patch or spray applied to the surface of an affected or injured area. The desired
concentration of the active compound in the secretory compositions/cocktails will depend on absorption, inactivation, and excretion and delivery rates of any enzymes, drugs, or compound in the secretory compositions/cocktail. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art. For example, a range of amounts of secretory compositions/cocktails are contemplated, including about 0.001, 0.01, 0.1, 0.5, 1, 10, 15, 20, 25, 50, 75, 100, 150, 200 or 250 mg or more of such compositions per kg body weight of the patient. Other amounts will be known to those of skill in the art and readily determined. In certain embodiments, the dosage of the secretory compositions/cocktails described above, will generally be in the range of about 0.001 mg to about 250 mg per kg body weight, specifically in the range of about 50 mg to about 200 mg per kg, and more specifically in the range of about 100 mg to about 200 mg per kg. In one embodiment, the dosage is in the range of about 150 mg to about 250 mg per kg. In another embodiment, the dosage is about 200 mg per kg.
In some embodiments, the molar concentration of the secretory
compositions/cocktails described above, in a pharmaceutical composition will be less than or equal to about 2.5 M, 2.4 M, 2.3 M, 2.2 M, 2.1 M, 2 M, 1.9 M, 1.8 M, 1.7 M, 1.6 M, 1.5 M, 1.4 M, 1.3 M, 1.2 M, 1.1 M, 1 M, 0.9 M, 0.8 M, 0.7 M, 0.6 M, 0.5 M, 0.4 M, 0.3 M or 0.2 M. In some embodiments, the concentration of the secretory
compositions/cocktails described above, will be less than or equal to about 0.10 mg/ml, 0.09 mg/ml, 0.08 mg/ml, 0.07 mg/ml, 0.06 mg/ml, 0.05 mg/ml, 0.04 mg/ml, 0.03 mg/ml or 0.02 mg/ml.
Actual dosage levels of the active ingredients in the compositions of the present invention may be varied so as to obtain an amount of the active ingredient, which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the activity of the particular therapeutic secretory compositions/cocktails in the formulation employed, or the ester, salt or amide thereof, the route of administration, the time of
administration, the rate of excretion or metabolism of the particular therapeutic secretory compositions/cocktails being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could prescribe and/or administer doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
If desired, the effective daily dose of the active compound may be
administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
The precise time of administration and amount of any particular compound that will yield the most effective treatment in a given patient will depend upon the activity, pharmacokinetics, and bioavailability of a particular compound,
physiological condition of the patient (including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage and type of
medication), route of administration, and the like. The guidelines presented herein may be used to optimize the treatment, e.g., determining the optimum time and/or amount of administration, which will require no more than routine experimentation consisting of monitoring the subject and adjusting the dosage and/or timing.
While the subject is being treated, the health of the patient may be monitored by measuring one or more of the relevant indices at predetermined times during a 24-hour period. All aspects of the treatment, including supplements, amounts, times of administration and formulation, may be optimized according to the results of such monitoring. The patient may be periodically reevaluated to determine the extent of improvement by measuring the same parameters, the first such reevaluation typically
occurring at the end of four weeks from the onset of therapy, and subsequent reevaluations occurring every four to eight weeks during therapy and then every three months thereafter. Therapy may continue for several months or even years, with a minimum of one month being a typical length of therapy for humans. Adjustments, for example, to the amount(s) of agent administered and to the time of
administration may be made based on these reevaluations.
Treatment may be initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage may be increased by small increments until the optimum therapeutic effect is attained.
Another aspect of the invention, relates to a method for providing a slow release of enzymes comprising the step of contacting the surface of an optical product with an effective amount of any of the aforementioned secretory compositions/cocktails. In some embodiments, the optical product is a contact lens.
Another aspect of the invention, relates to a method for removing urea comprising the step of contacting a medical device or clinical product with an effective amount of any of the aforementioned secretory compositions/cocktails. In some embodiments, the clinical product may comprise an artificial kidney dialyzates.
EXEMPLIFICATION
The following Examples have been included to provide guidance to one of ordinary skill in the art for practicing representative embodiments of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill can appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter. The following Examples are offered by way of illustration and not by way of limitation.
EXAMPLE 1
A novel, extremophilic fungal species was cultured, isolated, characterized and sequenced herein (FIG. 2). The whole genome of the novel, extremophilic fungal species has been sequenced and assembled. This novel fungal species secretes a cocktail of thermo-tolerant exo-enzymes. In addition, this fungal species digests cellular and genetic material in its surroundings under extreme temperatures. The organism has a variety of growth characteristics that can be exploited to provide a unique combination
of heat-resistant lipases, proteases, RNases, and DNases and antimicrobials that destroy biological material within minutes upon contact (FIG. I).
Non-naturally occurring countermeasures, such as addition of synthetic sources, have been used on the novel fungal species to generate novel cocktail of recombinant proteases and recombinant DNases.
EXAMPLE2
Recent results show that the purified, concentrated, and stabilized secretory enzyme compositions/cocktails efficiently destroy human cells and bacteria. The cocktails work on a variety of surfaces at different temperatures. The cocktail of enzymes and essential salts should destroy most cell types and viruses, leaving behind an edible, nontoxic mixture of amino-acids and nucleotides (FIG. 3).
EXAMPLE 3
Bacteria/fungal strains and culture conditions
The bacterial culture used in this study was Bacillus anthracis Sterne (-px02). Stock cultures of the organism were stored at -80 °C in brain heart infusion broth (BHI; RPI Cat# 50-488-526) containing 25% (v/v) glycerol. Monthly, frozen stock cultures were transferred to working cultures by plating on BHI agar slants/plates and incubating at 37 °C for 24 hrs. Prior to each experiment, cultures were incubated overnight in BHI broth at 37 °C on a rotary shaker set at 150 RPM. All cultures were diluted with BHI broth to desired cell numbers.
The fungal culture used in this study was TM-417. Stock cultures of the organism were stored at -80 °C in yeast protein glucose broth (YpG; 0.4% yeast extract, 0.1% K2HPO4, 0.05% MgS04, 1.5% glucose, pH 7.3) containing 25% (v/v) glycerol. Monthly, frozen stock cultures were transferred to working cultures by plating on YPG agar plates and incubating at 55 °C for 4 days.
Preparation of fungal extract
Isolated cultures were transferred to Fembach flasks containing 250 mL of DYpG (0.4% yeast extract, 0.1% K2HP04, 0.05% MgS04, 1.5% glucose, 0.2% DNA, pH 7.3) broth. Each flask was placed on a shaker (115 RPMs) and incubated at 55 °C for three days. After three days, the flask was allowed to incubate statically for 2 additional days. Cell mass was removed from the sample by vacuum filtration through coarse filter paper (Fisherbrand Filter Paper P8). The filtrate was then filtered through sterile cheese cloth (06-665-28), then under vacuum through fine filter paper (Fisherbrand Filter Paper P4), frozen (-80 °C), and
lyophilized. The lyophilized powder was stored at -20 °C and was the fungal extract (FE) used for all experiments.
Antimicrobial Activity of the fungal extract against B. cmthracis Sterne
The antimicrobial activity of the FE against B. anthracis Sterne in saline can be seen in FIG. 4. The FE was able to reduce the final cell numbers of B. anthracis Steme levels by 3 logs following a lS-min treatment at room temperature. To see if non-inoculated growth media had an impact on B. anthracis Sterne, DypG growth media was lyophilized and applied to B. anthracis Steme for the same amount of time and at the same concentration. Treatment of B. anthracis Sterne for 120 min with DypG growth media resulted in a 1 log reduction, demonstrating that the observed antimicrobial activity was related to the FE.
Lyophilized FE was added (%W/V) to saline inoculated with B. anthracis with a final cell density of 6 log CFU/mL and allowed to incubate at room temperature. Following incubation, the cells were washed twice with saline via centrifugation (13,400 RPM). The final washed pellet was suspended in brain-heart infusion (BFfl) broth, serially diluted, and plated on BHI agar plates. A 3-tube most-probable-number enumeration in BHT broth was performed for samples that resulted in negative plate counts. All data points were performed in triplicate.
FIG.4 shows the effect of the fungal extract (FE) (50% W/V) against B. anthracis. Briefly, lyophilized FE was added (50%W/V) to saline inoculated with B. anthracis for a final cell density of 6 log CFU/mL and allowed to incubate at room temperature. The treatment of B. anthracis with the FE resulted in a 3-log reduction after a 15 min treatment time. All data points were performed in triplicate. The limit of detection was 0.47 log CFU/mL, which correlated to a log reduction of -5.5 log CFU/mL as indicated by the dashed line. The limit of detection was 0.47 log CFU/mL, which correlated to a log reduction of -5.5 log CFU/mL as indicated by the dashed line.
Effect of temperature and storage on the efficacy of the fungal extract against B. anthracis Sterne
To determine the stability, the FE was either boiled for 10 min or stored at 20 °C for 24 hrs. The prolonged storage and boiling of the FE resulted in a dramatic decrease in antimicrobial activity (FIG.5). Sample that were boiled had a 44% decrease in efficacy against B. anthracis Sterne when compared to the control. The efficacy of FE that was stored for 24 hr at 20 "C was reduced by over 59%. Since the antimicrobial activity of the FE is
believed to be mostly protein based, boiling the FE for 10 min may have denatured some of the active proteins. It is known that TM-417 produces a large amount of proteases.
Prolonged unrefrigerated storage of the FE may have allowed the native proteases to act on the functional proteins present in the extract, decreasing the overall effectiveness of the FE overtime.
Prior to testing, two batches of FE (50% W/V) were made: 1) FE that was boiled for 10 mins, and 2) FE that sat at room temperature for 24 hr. B. anthracis was added to 5 mL of each FE batch for a final cell number of 6 log CFU/mL and allowed to incubate for 30 min at room temperature. Initial activity was determined by incubating B. anthracis (6 log
CFU/mL) for 30 mins in a freshly prepared solution of 50% W/V FE. Following incubation, cells were washed twice with saline via centrifugation (13,400 RPM). The final washed pellet was suspended in brain-heart infusion (BHI) broth, serially diluted, and plated on BUI agar plates.
FIG.5 shows the effect of boiling and room temperature storage on the efficacy of the FE against B. anthracis. Boiling and storage at room temperature greatly reduced the efficacy of the FE against B. anthracis. All data points were performed in triplicate.
Effect of water on the efficacy of the funzal extract against B. anthracis Sterne
The activity of an enzymes is usually impacted by the environment in which they are reconstituted. Since this extract is from a thermophilic organism, it was theorized that function proteins produced by TM-417 would be able to tolerate non-buffered environments. To test this theory, the FE (50%W/V) was dissolved in either saline, tap water, or distilled water and tested against B. anthracis Sterne (FIG. 6). Dissolving the FE in saline, tap water, or distilled water had no impact on its effectiveness against B. anthracis Steme.
Lyophilized FE was added to either saline, tap water, or reverse osmosis water for a final concentration of 50% W/V. The solution was inoculated with B. anthracis for a final cell density of 6 log CFU/mL and allowed to incubate at room temperature for 1 hr.
Following incubation, the cells were washed twice with saline via centrifugation (13,400 RPM). The final washed pellet was suspended in brain-heart infusion (BHI) broth, serially diluted, and plated on BHI agar plates.
FIG.6 shows the influence of water type on the efficacy of FE against B. anthracis. The FE (50%W/V) was dissolved in either saline, tap water, or distilled water and its ability to inactivate B. anthracis was assessed. It was found that there was not significant difference
between the antimicrobial activity of the FE when dissolved in three types of water. All data points were performed in triplicate.
Antimicrobial efficacy ofFE combined with Lvsozvme and Proteinase K against B. anthracis Sterne
To see if the effectiveness of the FE against B. anthracis Sterne could be improved, the FE was supplemented with a combination of proteinase K and lysozyme (10 or 100 units/mL; FIG. 7) or ampD (6 ug/uL) and phi29 lysozyme (2 \\%J\iV) (FIG. 8). The supplementation of the FE with proteinase K and lysozyme greatly enhanced the FE's antimicrobial activity at 37 "C. When supplemented with either 10 or 100 units/mL proteinase K and lysozyme, reductions >2.5 logs were observed when compared to viable cell counts from the untreated samples following a 4 hr treatment. Increasing lysozyme and proteinase K concentrations from 10 units/mL to 100 units/mL did not increase the antimicrobial activity. The supplementation of the FE with ampD (6 ug/uL) and phi29 lysozyme (2 ug/uL) resulted in > 5 log reduction in viable cell counts when treated for 2 hr at either 20 °C or 37 °C.
Lyophilized FE was added (10 %W/V) to saline containing Lysozyme (10 or 100 units/mL) and Proteinase K (10 or 100 units /mL) and inoculated with B. anthracis with a final cell density of 6 log CFU/mL and allowed to incubate for 4 hr at either room temperature or 37 °C. Following incubation, the cells were washed twice with saline via centrifugation (13,400 RPM). The final washed pellet was suspended in brain-heart infusion (BH1) broth, serially diluted, and plated on BHI agar plates. A 3-tube most-probable-number enumeration in BHI broth was performed for samples that resulted in negative plate counts.
FIG. 7A-C shows the antimicrobial activity of the FE (FIG. 7A) and the FE supplemented with either 10 units/mL (FIG. 7B) or 100 units/mL (FIG. 7C) of proteinase K and lysozyme against B. anthracis Sterne. Antimicrobial activity was assessed at 20 °C and 37 °C. Supplementation with proteinase K and lysozyme enhanced the antimicrobial activity of the FE. All data points were performed in triplicate. Treatments were compared to initial cells numbers using a one-tail t-test with a 95% confidence interval. Treatments grouped using Tukey's-test with a 95% confidence interval. All data points were performed in triplicate. The limit of detection was 0.47 log CFU/mL, which correlated to a log reduction of -5.5 log CFU/mL as indicated by the dashed line.
Antimicrobial efficacy of FE combined with ampD and phi29 lysozyme against B. anthracis Sterne
Lyophilized FE was added (10 %W/V) to saline containing ampD and
phi29 lysozyme (2 μg/μL) and inoculated with B. anthracis with a final cell density of 6 log CFU/mL and allowed to incubate for 2 hr at either room temperature or 37 "C. Following incubation, the cells were washed twice with saline via centrifugation (13,400 RPM). The final washed pellet was suspended in brain-heart infusion (BHI) broth, serially diluted, and plated on BHI agar plates. A 9-tube most-probable-number enumeration in BHI broth was performed for samples that resulted in negative plate counts. FIG. 8 shows antimicrobial activity of the FE supplemented with of ampD and of phi29 lysozyme
against B. anthracis Sterne. Antimicrobial activity was assessed at 20 °C and 37 °C. All data points were performed in triplicate. Treatments were compared to initial cells numbers using a one-tail t-test with a 95% confidence interval. Treatments grouped using Tukey's-test with a 95% confidence interval. All data points were performed in triplicate. The limit of detection was 0.47 log CFU/mL, which correlated to a log reduction of -5.5 log CFU/mL as indicated by the dashed line.
Antimicrobial efficacy ofFE combined with ampD and phi29 Ivsozvme against B. anthracis Sterne on surfaces
A potential application of the FE would be to use it to inactive B. anthracis Sterne on a variety of surfaces such as stainless steel (FIG. 9) and glass (FIG. 10). B. anthracis Sterne was dried onto the surface of glass or stainless steel coupons and treated with FE supplemented with ampD (6 μg/μL.) and phi29 lysozyme (2 μ&μϊ-). The supplemented FE reduced viable B. anthracis Sterne levels on glass and stainless steel by more than 3 logs at room temperature following a 120 min and 30 min treatment respectively.
Sterile stainless steel (304) or glass coupons were placed in a sterile glass petri dish containing sterile filter paper and inoculated for a final pathogen levels of 4 or 7 log CFU/cm2 respectively. The coupons were dried overnight in a biosafety cabinet at room temperature. The initial numbers of B. anthracis Sterne on the coupons were determined by vortexing the coupons in sterile maximum recovery diluent (MRD) for 10 seconds at maximum speed. The inoculated chips were treated by applying 100 μL of FE (10% W/V) containing ampD (6 μg/μL.) and phi29 lysozyme (2 μg/μL) to the coupons surface and
allowing it to soak for a specific period of time. After treatment, the chips were immediately transferred into 30 mL of sterile MRD and soaked for 10 minutes followed by vortexing at maximum speed (10 sec). A dilution series was performed and plated BHI agar. A 3-tube most probable number assay (MPN) was used for samples that resulted in negative plate counts. Samples were incubated overnight at 37°C. Following incubation, the samples with positive MPN were streaked onto BHI agar for confirmation. FIG. 9 shows the efficacy of FE supplemented with of ampD and 2 lysozyme against Bacillus
anthracis on stainless steel (304) coupons. Treatments were compared to initial cells numbers using a one-tail t-test with a 95% confidence interval. Treatments grouped using Tukey's-test with a 95% confidence interval. FIG. 10 shows the efficacy of FE
supplemented with 6 ug/uL of ampD and
lysozyme against Bacillus anthracis on glass coupons. Treatments were compared to initial cells numbers using a one- tail t-test with a 95% confidence interval. Treatments grouped using Tukey's-test with a 95% confidence interval.
REFERENCES
1. Landry KS, Levin RE. Characterization of a recently purified thermophilic DNase from a novel thermophilic fungus. Appl Biochem Biotechnol. (2014) 173(7): 1587- 96.
2. Landry KS, Vu A, Levin RE. Purification of an inducible DNase from a thermophilic fungus. InlJMalSci. (2014) 15(1):1300-14.
3. Landry KS, Levin RE. Purification and characterization ofiso- ribonucleases from anovel thermophilic fungus.
4. Landry KS, Levin RE. Development of a novel affinity membrane purification system for deoxyribonucleasc. Appl Biochem Biotechnol. (2014)
172(4): 1964-9.
5. Tullis, RH and Rubin, H. Calcium protects DNase I from Proteinase K: A new method for the removal of contaminating RNase from DNase. Analytical
Biochemistry. (1998) 107:260- 264
INCORPORATION BY REFERENCE
All of the U.S. patents and U.S. published patent applications cited herein are hereby incorporated by reference.
EQUIVALENTS
Those skilled in the ait will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (42)
1. A method for reducing an amount or an activity of microorganisms, comprising:
contacting a substrate comprising the microorganisms with a composition comprising one or more enzymes derived from an extremophilic fungal species, thereby reducing the amount or the activity of the microorganisms.
2. The method of claim 1, wherein the extremophilic fungal species is TM-417.
3. The method of claim 1, wherein the extremophilic fungal species is at least about 80% homologous to TM-417.
4. The method of claim 1, wherein the one or more enzymes comprise at least one enzyme selected from the group consisting of urease, DNase, RNase, exonuclease, endonuclease, ribonuclease, amylase, acetoin reductase, an indole-3 -acetamide hydrolase, a tryptophan monooxygenase, an acetolactate synthetase, an Π-aceto lactate decarboxylase, a pyruvate decarboxylase, a diacetyl reductase, a butanediol dehydrogenase, an
aminotransferase, a tryptophan decarboxylase, an amine oxidase, an indole-3 -pyruvate decarboxylase, an indole-3- acetaldehyde dehydrogenase, a tryptophan side chain oxidase, a nitrile hydrolase, a nitrilase, a peptidase, a protease, an adenosine phosphate
isopentenyltransferase, a phosphatase, an adenosine kinase, an adenine
phosphoribosyltransferase, CYP735A, a 5'ribonucleotide phosphohydrolase, an adenosine nucleosidase, a zeatin cis-trans isomerase, a zeatin 0- glucosyltransferase, a β-glucosidase, a cis-hydroxylase, a CK cis-hydroxylase, a CK N- glucosyltransferase, a 2,5-ribonucleotide phosphohydrolase, an adenosine nucleosidase, a purine nucleoside phosphorylase, a zeatin reductase, a hydroxylamine reductase, a 2-oxoglutarate dioxygenase, a gibberellic 2B/3B hydrolase, a gibberellin 3 -oxidase, a gibberellin 20-oxidase, a chitosanase, a chitinase, a β- 1,3-glucanase, a P-l,4-glucanase, a fJ-l,6-glucanase, an aminocyclopropane-l-carboxylic acid deaminase, chitosanase, a cellulase, a lipase, a lignin oxidase, a protease, a glycoside hydrolase, a phosphatase, a nitrogenase, a nuclease, an amidase, a nitrate reductase, a nitrite reductase, an amylase, an ammonia oxidase, a ligninase, a glucosidase, a phospholipase, a phytase, a pectinase, a glucanase, a sulfatase, a xylanase, an endocellulase, an exocellulase, a β-glucosidase, phospholipase, acetate kinase, phosphotransacetylase, lactate dehydrogenase, pyruvate decarboxylase (PDC), alcohol dehydrogenase (ADH), xylose isomerase,
xylulokinase, L-arabinose isomerase, L-ribulose-5- phosphate 4-epimerase, a glycan strand- cleaving enz>'me/glycosidase, N-acetylglucosaminidase, acetylmutamyl-L-alanine amidase, lysozyme, lytic transglycosylase and peptidoglycan endopeptidase.
5. The method of claim 1 , wherein the one or more enzymes comprise two or more enzymes.
6. The method of claim 1, wherein the one or more enzymes comprise three or more enzymes.
7. The method of claim 1, wherein the one or more enzymes comprise four or more enzymes.
8. The method of claim 1 , wherein the one or more enzymes have at least about a 25-fold increase in specific activity when purified using size exclusion chromatography in combination with an affinity based membrane purification system.
9. The method of claim 1, wherein the one or more enzymes have at least about a 100-fold increase in specific activity when purified using size exclusion chromatography in combination with an affinity based membrane purification system.
10. The method of claim 1, wherein the one or more enzymes have at least about a 200-fold increase in specific activity when purified using size exclusion chromatography in combination with an affinity based membrane purification system.
11. The method of claim 1 , wherein the one or more enzymes is at least about 50% pure.
12. The method of claim 1, wherein the one or more enzymes is at least about 75% pure.
13. The method of claim 1 , wherein the one or more enzymes is at least about 95% pure.
14. The method of claim 1 , wherein the composition comprises ampD.
15. The method of claim 1 , wherein the composition comprises lysozyme.
16. The method of claim 1, wherein the composition comprises phi29 lysozyme.
17. The method of claim 1, wherein the microorganisms comprise bacteria, fungi, viruses, or yeast.
18. The method of claim 1, wherein the microorganisms comprise Bacillus anthracis.
19. The method of claim 1 , wherein the activity of the microorganisms comprises
pathogenicity.
20. The method of claim 1, wherein the activity of the microorganisms comprises viability.
21. The method of claim 1 , wherein the activity of the microorganisms comprises reproduction.
22. The method of claim 1, wherein the activity of the microorganisms comprises metabolism.
23. The method of claim 1, wherein the activity of the microorganisms comprises toxin production.
24. The method of claim 1, wherein the amount or the activity of the
microorganisms is reduced by at least about 10%.
25. The method of claim 1, wherein the amount or the activity of the
microorganisms is reduced by at least about 50%.
26. The method of claim 1, wherein the amount or the activity of the
microorganisms is reduced by at least about 70%.
27. The method of claim 1, wherein the amount or the activity of the
microorganisms is reduced by at least about 95%.
28. The method of claim 1, wherein the amount or the activity of the
microorganisms is reduced by at least about 99%.
29. The method of claim 1, wherein the substrate comprises a liquid.
30. The method of claim 1, wherein the substrate comprises water.
31. The method of claim 1, wherein the substrate comprises a solid.
32. The method of claim 1, wherein the substrate comprises steel.
33. The method of claim 1, wherein the substrate comprises glass.
34. The method of claim 1, wherein the substrate is part of a product or system selected from the group consisting of medical device, clinical product, agricultural specimen, environmental specimen, manufacturing sample, industrial system, transportation, marine system, and household system.
35. The method of claim 34, wherein the medical device is a catheter, stent, IV, or surgical tool.
36. The method of claim 34, wherein the agricultural specimen is a food, farm product, water supply, waste water, fertilizer wastewater, or sludge.
37. The method of claim 34, wherein the environmental specimen is a lake, pond, fountain, or pool.
38. The method of claim 34, wherein the clinical product is an artificial kidney dialysate.
39. The method of claim 34 wherein the manufacturing sample is a machine for processing samples.
40. The method of claim 34, wherein the industrial system is a cooling water system, a heat exchanger, a pulp and paper manufacturing system, food processing system, a metalworking system, a photo processing system, a reverse osmosis membrane, a water processing system, a flow channel, a turbine, a solar panel, a pressurized water reactor, an injection and spray nozzle, a steam generator, process equipment, a secondary oil recovery injection well, or piping.
41. The method of claim 34, wherein the marine system comprises an offshore oil and gas pipeline, off-shore oil rig, environments within a boat or oil rig, or a boat hull.
42. The method of claim 34, wherein the household environment comprises a cutting surface, a sink, a counter-top, a shower, a vase, a pet food bowl, a water bowl, decorative water landscaping, or a bird bath.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662318597P | 2016-04-05 | 2016-04-05 | |
US62/318,597 | 2016-04-05 | ||
PCT/US2017/026090 WO2017176853A1 (en) | 2016-04-05 | 2017-04-05 | Fungal species, compositions derived therefrom, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2017246664A1 AU2017246664A1 (en) | 2018-11-08 |
AU2017246664B2 true AU2017246664B2 (en) | 2024-01-18 |
Family
ID=60001431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2017246664A Active AU2017246664B2 (en) | 2016-04-05 | 2017-04-05 | Fungal species, compositions derived therefrom, and uses thereof |
Country Status (3)
Country | Link |
---|---|
US (2) | US10939685B2 (en) |
AU (1) | AU2017246664B2 (en) |
WO (1) | WO2017176853A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
CN110643620B (en) * | 2019-10-22 | 2021-05-28 | 怀化学院 | High-activity poria cocos cellulose endonuclease gene and protein and recombinant vector thereof |
CN114317279A (en) * | 2021-12-20 | 2022-04-12 | 贵州省生物研究所 | High-quality culture medium formula for separating pleurotus nebrodensis associated with fungi |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194758A1 (en) * | 2001-08-10 | 2003-10-16 | Mycologics, Inc. | Methods for the identification of fungal glucose utilization inhibitors and antifungal agents |
WO2009155115A2 (en) * | 2008-05-30 | 2009-12-23 | Reactive Surfaces, Ltd. | Coatings and surface treatments having active enzymes and peptides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4426396A (en) | 1981-06-11 | 1984-01-17 | Union Oil Company Of California | Preservation of harvested crops and animal feedstuffs |
WO2000026334A1 (en) | 1998-10-30 | 2000-05-11 | Metrex Research Corporation | Simultaneous cleaning and decontaminating compositions and methods |
WO2005013898A2 (en) * | 2003-07-11 | 2005-02-17 | Vaxin, Inc. | Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
CA2862363C (en) * | 2012-02-02 | 2021-06-08 | Joan M. Fallon | Enzyme compositions and use thereof for wound healing |
-
2017
- 2017-04-05 US US16/091,279 patent/US10939685B2/en active Active
- 2017-04-05 WO PCT/US2017/026090 patent/WO2017176853A1/en active Application Filing
- 2017-04-05 AU AU2017246664A patent/AU2017246664B2/en active Active
-
2021
- 2021-01-27 US US17/159,870 patent/US20210251241A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030194758A1 (en) * | 2001-08-10 | 2003-10-16 | Mycologics, Inc. | Methods for the identification of fungal glucose utilization inhibitors and antifungal agents |
WO2009155115A2 (en) * | 2008-05-30 | 2009-12-23 | Reactive Surfaces, Ltd. | Coatings and surface treatments having active enzymes and peptides |
Non-Patent Citations (1)
Title |
---|
Landry, Kyle S., "Purification and Characterization of Novel Nucleases from a Thermophilic Fungus" (2012). Masters Theses 1911 - February 2014. 804. Retrieved online from: https://scholarworks.umass.edu/theses/804 * |
Also Published As
Publication number | Publication date |
---|---|
US20210251241A1 (en) | 2021-08-19 |
AU2017246664A1 (en) | 2018-11-08 |
US10939685B2 (en) | 2021-03-09 |
WO2017176853A1 (en) | 2017-10-12 |
US20190110481A1 (en) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210251241A1 (en) | Fungal species, compositions derived therefrom, and uses thereof | |
Wei et al. | Fiber degradation potential of natural co-cultures of Neocallimastix frontalis and Methanobrevibacter ruminantium isolated from yaks (Bos grunniens) grazing on the Qinghai Tibetan Plateau | |
Barati et al. | Bacterial pretreatment of microalgae and the potential of novel nature hydrolytic sources | |
Javed et al. | An innovative approach for hyperproduction of cellulolytic and hemicellulolytic enzymes by consortium of Aspergillus niger MSK-7 and Trichoderma viride MSK-10 | |
Amadi et al. | Process optimization for simultaneous production of cellulase, xylanase and ligninase by Saccharomyces cerevisiae SCPW 17 under solid state fermentation using Box-Behnken experimental design | |
Hebbale et al. | Saccharification of macroalgal polysaccharides through prioritized cellulase producing bacteria | |
Arijit et al. | Improved production and purification of pectinase from Streptomyces sp. GHBA10 isolated from Valapattanam mangrove habitat, Kerala, India | |
Essghaier et al. | Antimicrobial behavior of intracellular proteins from two moderately halophilic bacteria: strain J31 of Terribacillus halophilus and strain M3-23 of Virgibacillus marismortui | |
EP2782991B1 (en) | Cleaning fluid | |
Lee et al. | Influences of surfactant Tween 80 on the gas production, cellulose digestion and enzyme activities by mixed rumen microorganisms | |
Al Abboud et al. | Halostability and thermostability of chitinase produced by fungi isolated from salt marsh soil in subtropical region of Saudi Arabia | |
CN106987572A (en) | A kind of method that anaerobic fermentation maize straw produces zytase | |
Sreena et al. | Production of cellulases and xylanase from Bacillus subtilis MU S1 isolated from protected areas of Munnar wildlife division | |
WO2016044723A1 (en) | Method for treatment of microorganisms during propagation, conditioning and fermentation using hops acid extracts and nisin | |
Sami et al. | Preliminary studies on the production of endo-1, 4-β–Dglucanases activity produced by Enterobacter cloacae | |
Mudau et al. | Screening and identification of endomannanase-producing microfungi from hypersaline environments | |
CN103892126B (en) | Modifying agent raised by livestock and poultry colony house | |
de Queiroz Baptista et al. | Effects of gamma radiation on enzymatic production of lignolytic complex by filamentous fungi | |
Krestyanova et al. | Characteristics of fungal strains producing thermostable xyloglucanases from the Russian National Collection of industrial microorganisms | |
Javanmard et al. | Investigating cellulase producing potential of two Iranian Thermoascus aurantiacus isolates in submerged fermentation | |
Sekar et al. | Production of industrial important enzymes from marine isolates | |
Djafar et al. | Isolation of endophytic bacteria from palm oil fruits and characterization of their lipases | |
Bakri et al. | Enzymatic activity of the endophytic Fusarium species strains isolated from wheat | |
Bhimba et al. | Characterization of extracellular amylase enzyme produced by Aspergillus flavus MV5 isolated from mangrove sediment | |
RU2673967C1 (en) | STRAIN OF BACTERIA PAENIBACILLUS SPECIES - A PRODUCER OF β-GLUCANASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |